Epidemiology and Medical statistics Books

Book SynopsisIn the wake of COVID, it's more important than ever to understand epidemicshow they emerge and what we can do to fight back.Part of Bloomsbury's Q&A Health Guides series, this book takes a balanced approach, offering a blend of both epidemiological science and practical suggestions grounded in that science. The volume's 47 questions begin with the basics, including which diseases are most likely to become epidemics, which have historically been the deadliest, and how factors such as climate change will affect the emergence of future pandemics. Next, the book answers readers' questions regarding how epidemics spread and how strategies such as disease reporting, quarantine, and vaccine development can help combat them. Readers will also find questions offering guidance on how to protect yourself during a widespread disease event, including which information sources to trust and how personal choices can influence exposure risk. The final section of questions examiTable of ContentsSeries Forward Acknowledgments Introduction Guide to Health Literacy Common Misconceptions about Epidemics and Pandemics 1. Epidemics are caused by highly communicable microbial agents 2. Epidemics are only caused by novel pathogens for which humans have no immunity 3. Pandemics are the result of the highly interconnected world we live in, where no country is more than 24 hours away from any other 4. Epidemics are only dangerous for people who are already unhealthy 5. More investment in vaccine research and development can prevent future epidemics Questions and Answers The Basics 1. What is an epidemic? What is a pandemic? 2. Which diseases are most likely to cause epidemics and pandemics? 3. Are there places on earth where epidemic diseases are more common? 4. Who decides when an epidemic has emerged and who decides when it’s over? What criteria are used to do so? 5. What have been the most lethal epidemics in recorded history? 6. Does climate change influence the prevalence of epidemic disease? 7. Which diseases pose the greatest threat to humanity? 8. Can future pandemics be prevented? How Epidemics and Pandemics Begin and Spread How Epidemics and Pandemics Begin and Spread 9. How are epidemic diseases transmitted? 10. How do epidemic diseases spread? 11. How much of a pathogen is needed to create infection? 12. What is a basic reproductive number? 13. What is an incubation period and how can it affect the spread of an epidemic disease? 14. What is a disease’s infectious period and how can it influence an epidemic? 15. Why do diseases mutate over time, and how does this affect the spread of epidemics? 16. What factors increase susceptibility to epidemic disease? 17. What is a super-spreader and what role do they play in epidemics? 18. What does it mean to be asymptomatic, and can an asymptomatic person spread disease? 19. Is there a natural progression for an epidemic disease? Will an epidemic or pandemic eventually die out on its own? Combatting Epidemics and Pandemics 20. In the United States, who is in charge of organizing a response to an epidemic? 21. What institutions are responsible for global responses to pandemics? 22. What is disease reporting and why is it important during an epidemic? 23. What is contact tracing and how does it reduce the spread of disease? 24. How do vaccines work? How effective are they? 25. How do researchers create vaccines for new diseases? 26. What non-pharmaceutical measures work to combat epidemics when effective vaccines or antibiotics don’t exist? 27. What is the difference between quarantine and isolation? How do they help combat epidemics? 28. What are universal public health precautions? 29. Do public health mandates to control human behavior work? 30. Covid-19 revealed political differences in the way pandemics are managed. Is this a new phenomenon? Protecting Yourself during an Epidemic or Pandemic 31. Will past exposure to an epidemic disease protect against future exposures to that disease? 32. What personal choices influence exposure to disease? 33. What are the most effective ways to protect oneself when an epidemic or pandemic occurs? 34. Is handwashing effective for reducing exposure to epidemic diseases? 35. Can a face covering protect me from epidemic diseases? 36. Which surfaces should be cleaned to minimize the risk of infection, and what sort of cleaning products work best? 37. Does social distancing work to reduce exposure to epidemic diseases? 38. Are there dietary and exercise routines that improve immunity? 39. When someone in your household gets an epidemic disease, what precautions should be taken? 40. What lifestyle choices can improve mental health during an epidemic? 41. What are trustworthy organizations and sources of information to consult during an epidemic? The Impact of Epidemics and Pandemics 42. Do epidemics affect certain groups of people more than others? 43. Can epidemics and pandemics lead to health problems even after they’ve officially ended? 44. In what other ways can an epidemic or pandemic negatively impact physical health? 45. How can an epidemic or pandemic affect individuals’ mental and social well-being? 46. How do pandemics affect the economy, politics, and culture? 47. How do epidemics and pandemics stigmatize certain people? Case Studies 1. So Much for the 6-Foot Social Distancing Rule: The Tale of a Loudmouth and Captive Employee 2. Reports of “Mongolian Purple Plague” Spark Riots in the United States 3. A Smallpox Bioterrorism Event Closes New York City and Creates a Public Health Emergency 4. Spreading Monkeypox: The Extreme Burdens of Poverty and Limited Access to Health Care Services 5. Digital Breadcrumbs Expedite Contact Tracing during a Measles Outbreak Glossary Directory of Resources Index

Read more less

Book SynopsisMaintaining a practical perspective, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition explores statistics used in day-to-day clinical pharmacology work. The book is a starting point for those involved in such research and covers the methods needed to design, analyze, and interpret bioequivalence trials; explores when, how, and why these studies are performed as part of drug development; and demonstrates the methods using real world examples. Drawing on knowledge gained directly from working in the pharmaceutical industry, the authors set the stage by describing the general role of statistics. Once the foundation of clinical pharmacology drug development, regulatory applications, and the design and analysis of bioequivalence trials are established, including recent regulatory changes in design and analysis and in particular sample-size adaptation, they move on to related topics in clinical pharmacology involving the use of cross-over Trade Review"The two authors are well-respected statisticians with numerous publications in BE and broad pharmaceutical industry experience. … The book is written in plain language and statistics is presented with minimum mathematical proof, which makes it a great introduction and reference for statisticians and clinical pharmacologists. With case studies and associated SAS and R codes included in the book and website, both statisticians and clinical pharmacologists will find this book helpful in understanding the context to use a method and implementing the ready-to-use codes. Particularly, each chapter begins with an interesting real-life story of the authors working as statisticians in the pharmaceutical industry, which makes the reading delightful. …In summary, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition, provides an update on regulatory recommendations, statistical methods, and applications in clinical pharmacology and BE studies to support drug product development. With its inclusion of SAS and R codes, this book will be a valuable reference for pharmaceutical scientists, statisticians, and regulators working in these areas."—Wangjie Sun and Wenlei Jiang, US Food and Drug Administration, in Journal of the American Statistical Association, January 2018"This book is a second edition of the authors’ take on the concepts and methods in the analysis and design of bioequivalence studies, supported by references to regulation authorities’ guidelines ... The authors are working in the pharmaceutical industry and therefore bring a view from the inside compared to the other reference work in the field by academics … Throughout the book, different examples with data and codes are provided both showing and not showing bioequivalence to facilitate the learning process. … To conclude, this book covers efficiently the statistical methods of bioequivalence testing and their many applications in clinical pharmacology. Furthermore, the dense reference list provides a helpful guide for the reader to go in deeper details on topics of interest."—Julie Bertrand, Faculté de Médecine Bichat, IAME, in Journal of Biopharmaceutical Statistics, May 2017"The first edition of Bioequivalence and Statistics in Clinical Pharmacology was a classic text book for researchers and statisticians in the field of clinical pharmacology and pharmaceutical industry. This new second edition is a timely update with the inclusion of new areas such as adaptive bioequivalence trials, scaled average bioequivalence testing, and vaccine trials. This is one of few books in the literature with the focus on statistical issues in clinical pharmacology and bioequivalence. The topics it covers are critical for understanding the pharmacology of an investigational drug, and are becoming increasingly important in the era of precision medicine. The book is just as well structured as the first edition, in an accessible, thorough, and clear manner. Case studies and associated SAS code included in the book are extremely helpful. In summary, the book is a most welcome addition to the collection of pharmaceutic statisticians and researchers in clinical pharmacology." —Liang Fang, Director of Biostatistics, Gilead Sciences Inc."Bioequivalence and Statistics in Clinical Pharmacology, Second Edition, provides readers with a statistical background of bioequivalence and presents several special topics in clinical pharmacology. This second edition contains updated and extended discussions of these topics and includes new chapters on adaptive bioequivalence studies, scaled average bioequivalence, and vaccine trials. The book’s presentation is comprehensive and clear, and is complimented by numerous illustrations, examples, and computer programs with data analyses. Scientists and practitioners working in industry, regulatory authorities, and academia will find this book useful, interesting, and enjoyable due to the delightful and instructive stories featured in the introductions of each chapter, the various important and relevant topics covered by these chapters, and the informative and practical technical appendices."—Laszlo Endrenyi, Professor Emeritus, University of TorontoPraise for the First Edition:"… the book provides a good introduction to common uses of statistics in early phases of the drug development process by using a good mix of technical detail, intuitive understanding and factual knowledge. … personal accounts together with the numerous real data examples which are accompanied by SAS code for analysis and the opportunity to download the data to gain first-hand experience are the best features of the book. … the authors did a fine job in providing an introduction to statistics in the early stages of the drug development process. The availability of real example data allows the reader to engage himself easily in the topic and the long experience of the authors ensures that many different aspects of pharmacological studies are discussed."—Thomas Jaki, Lancaster University, Journal of the Royal Statistical Society, Series A, 2010"I really enjoyed reading this book. Each chapter includes an excellent introduction based on Scott Patterson's experience working as a biometrician. This will especially be of interest to young statisticians starting their career in the pharmaceutical industry. Therefore, I strongly recommend this book to all pharmaceutical statisticians to learn more of the challenging statistical problems being generated in drug development. In addition, the presented material provides a springboard for all scientists from academia who are looking to do research in this area of medical applications."—Dieter Haushcke, Biometrics, September, 2006"The authors formulate bioequivalence exhaustively and clearly. … Given the background of the authors, they constitute a key piece of social information in understanding the context in which clinical pharmacology research develops within the pharmaceutical industry."—Journal of Biopharmaceutical Statistics"The two authors are well-respected statisticians with numerous publications in BE and broad pharmaceutical industry experience. … The book is written in plain language and statistics is presented with minimum mathematical proof, which makes it a great introduction and reference for statisticians and clinical pharmacologists. With case studies and associated SAS and R codes included in the book and website, both statisticians and clinical pharmacologists will find this book helpful in understanding the context to use a method and implementing the ready-to-use codes. Particularly, each chapter begins with an interesting real-life story of the authors working as statisticians in the pharmaceutical industry, which makes the reading delightful. …In summary, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition, provides an update on regulatory recommendations, statistical methods, and applications in clinical pharmacology and BE studies to support drug product development. With its inclusion of SAS and R codes, this book will be a valuable reference for pharmaceutical scientists, statisticians, and regulators working in these areas."—Wangjie Sun and Wenlei Jiang, US Food and Drug Administration, in Journal of the American Statistical Association, January 2018"This book is a second edition of the authors’ take on the concepts and methods in the analysis and design of bioequivalence studies, supported by references to regulation authorities’ guidelines ... The authors are working in the pharmaceutical industry and therefore bring a view from the inside compared to the other reference work in the field by academics … Throughout the book, different examples with data and codes are provided both showing and not showing bioequivalence to facilitate the learning process. … To conclude, this book covers efficiently the statistical methods of bioequivalence testing and their many applications in clinical pharmacology. Furthermore, the dense reference list provides a helpful guide for the reader to go in deeper details on topics of interest."—Julie Bertrand, Faculté de Médecine Bichat, IAME, in Journal of Biopharmaceutical Statistics, May 2017"The first edition of Bioequivalence and Statistics in Clinical Pharmacology was a classic text book for researchers and statisticians in the field of clinical pharmacology and pharmaceutical industry. This new second edition is a timely update with the inclusion of new areas such as adaptive bioequivalence trials, scaled average bioequivalence testing, and vaccine trials. This is one of few books in the literature with the focus on statistical issues in clinical pharmacology and bioequivalence. The topics it covers are critical for understanding the pharmacology of an investigational drug, and are becoming increasingly important in the era of precision medicine. The book is just as well structured as the first edition, in an accessible, thorough, and clear manner. Case studies and associated SAS code included in the book are extremely helpful. In summary, the book is a most welcome addition to the collection of pharmaceutic statisticians and researchers in clinical pharmacology." —Liang Fang, Director of Biostatistics, Gilead Sciences Inc."Bioequivalence and Statistics in Clinical Pharmacology, Second Edition, provides readers with a statistical background of bioequivalence and presents several special topics in clinical pharmacology. This second edition contains updated and extended discussions of these topics and includes new chapters on adaptive bioequivalence studies, scaled average bioequivalence, and vaccine trials. The book’s presentation is comprehensive and clear, and is complimented by numerous illustrations, examples, and computer programs with data analyses. Scientists and practitioners working in industry, regulatory authorities, and academia will find this book useful, interesting, and enjoyable due to the delightful and instructive stories featured in the introductions of each chapter, the various important and relevant topics covered by these chapters, and the informative and practical technical appendices."—Laszlo Endrenyi, Professor Emeritus, University of TorontoPraise for the First Edition:"… the book provides a good introduction to common uses of statistics in early phases of the drug development process by using a good mix of technical detail, intuitive understanding and factual knowledge. … personal accounts together with the numerous real data examples which are accompanied by SAS code for analysis and the opportunity to download the data to gain first-hand experience are the best features of the book. … the authors did a fine job in providing an introduction to statistics in the early stages of the drug development process. The availability of real example data allows the reader to engage himself easily in the topic and the long experience of the authors ensures that many different aspects of pharmacological studies are discussed."—Thomas Jaki, Lancaster University, Journal of the Royal Statistical Society, Series A, 2010"I really enjoyed reading this book. Each chapter includes an excellent introduction based on Scott Patterson's experience working as a biometrician. This will especially be of interest to young statisticians starting their career in the pharmaceutical industry. Therefore, I strongly recommend this book to all pharmaceutical statisticians to learn more of the challenging statistical problems being generated in drug development. In addition, the presented material provides a springboard for all scientists from academia who are looking to do research in this area of medical applications."—Dieter Haushcke, Biometrics, September, 2006"The authors formulate bioequivalence exhaustively and clearly. … Given the background of the authors, they constitute a key piece of social information in understanding the context in which clinical pharmacology research develops within the pharmaceutical industry."—Journal of Biopharmaceutical StatisticsTable of ContentsBioequivalence & Biopharmaceutical DevelopmentDrug Development and Clinical PharmacologyAims of This BookBiopharmaceutical DevelopmentClinical PharmacologyStatistics in Clinical PharmacologyStructure of the BookHistory and Regulation of BioequivalenceWhen and How BE Studies Are PerformedWhy Are BE Studies Performed?Deciding When Formulations Are BioequivalentPotential Issues with TOST BioequivalentCurrent International RegulationSome Practical NotesTesting for Average BioequivalenceBackgroundLinear Model for 2 x 2 DataApplying the TOST ProcedureCarry-over, Sequence, and Interaction EffectsChecking Assumptions Made about the Linear ModelPower and Sample Size for ABE in the 2 x 2 DesignExample Where Test and Reference Are Not ABENonparametric AnalysisBE Studies with More Than Two PeriodsBackgroundThree-period DesignsWithin-subject VariabilityRobust Analyses for Three Period DesignsFour-period DesignsDesignes with More Than Two TreatmentsAdjusting for Multiple TestingNonparametric Analyses of TmaxTechnical appendix: EfficiencyTables of DataSpecial Topics in BioequivalenceDealing with Special BE ChallengesRestricted Maximum Likelihood ModellingFailing BE and the DER AssessmentSimulationData-based SimulationCarry-overOptimal DesignsDetermining Trial SizeWhat Outliers Are and How to Handle Their DataBayesian BE AssessmentAdaptive Bioequivalence TrialsBackgroundTwo-stage design for testing for ABETOST using the standard combination testExample of using the standard combination testThe maximum combination testExample of using the maximum combination testConditional errors and conditional powerAlgorithm for sample size re-estimationOperating characteristicsConclusionsTechniccal Appendix: R codeScaled Average Bioequivalence TestingBackgroundScaled Average Bioequivalence in EuropeScaled Average Bioequivalence in USADiscussion and CautionsClinical PharmacologyClinical Pharmacology Safety StudiesBackgroundFirst-time-in-humansSub-chronic Dosing StudiesFood-Effect Assessment and DDIsDose-ProportionalityTechnical AppendixQTcBackgroundModelling of QTc DataInterpreting the QTc Modelling FindingsDesign of a Thorough QTc Study in the FutureClinical Pharmacology Efficacy StudiesBackgroundSub-chronic DosingPhase IIa and the Proof of ConceptPopulation PharmacokineticsPopulation and PharmacokineticsAbsolute and Relative BioavailabilityAge and Gender Pharmacokinetic StudiesEthnicityLiver DiseaseKidney DiseaseTechnical Appendix Vaccines & Epilogue Vaccine TrialsBrief Introduction to Vaccine Research and DevelopmentPhase I Vaccine StudiesProof of Concept and Phase IILot ConsistencyConcomitant VaccinationCross-over Trials in VaccinesEpilogue BibliographyIndex

Read more less

Book SynopsisDespite an enormous investment of effort throughout the world, cancer is still a major barrier to human longevity. Segi decided to devote his life to the fight against cancer by establishing worldwide comparative cancer statistics-one of the landmarks in cancer studies and in cancer prevention strategies.Table of ContentsChanging Cancer Patterns.- Changing Patterns of Cancer Incidence in Five Continents.- Trends of Cancer Incidence by Site and Histological Type in Osaka, Japan, 1963–1982.- Changes in Mortality of All Forms of Malignant Neoplasms among Japanese for the Last Decades.- Trends in Lung Cancer Mortality in 24 Countries.- Cancer Registration.- Cancer Registration in the Near Future.- The Cancer Registry and the Study of Occupational Cancer in Denmark.- Changes in Frequency of Less Common Cancers: An Early Warning System for Cancer Registries.- End Results of Cancer Patterns: From Population-Based Cancer Registry Data.- The Impact of the Computer on the Cancer Registry.- Migrant Study.- Cancer among Japanese-Americans in Hawaii.- Cancer Mortality among Polish Migrants.- Cancer Patterns among Koreans in Japan.- Topics in Cancer Epidemiology.- Passive Smoking and Cancer: An Epidemiological Review.- Exogenous Hormones and the Risk of Cancer.- Adult T-Cell Leukemia.- Chemical Risk Factors for Nasopharyngeal Carcinoma (NPC)—A Review.- Occupational Lung Cancer in a Tin Mine in South China.- Etiologic Clues from Cancer Mapping in the United States.- International Comparative Study.- Comparative Epidemiology of Cancer in the United States and Japan: Preventive Implications.- U S.-Japan Cooperative Cancer Research Program Report of a Workshop on Adult-Type Cancer under Age 30.- Rearranging Segi’s Cancer Mortality Statistics by Factor and Cluster Analysis.- Author Index.

Read more less

Book SynopsisConcise Encyclopedia of Biostatistics for Medical Professionals focuses on conceptual knowledge and practical advice rather than mathematical details, enhancing its usefulness as a reference for medical professionals. The book defines and describes nearly 1000 commonly and not so commonly used biostatistical terms and methods arranged in alphabetical order. These range from simple terms, such as mean and median to advanced terms such as multilevel models and generalized estimating equations. Synonyms or alternative phrases for each topic covered are listed with a reference to the topic.Table of ContentsDefines and describes nearly 1000 commonly and not so commonly used biostatistical terms and methods, arranged in alphabetical order

Read more less

Book SynopsisThe term health technology refers to drugs, devices, and programs that can improve and extend quality of life. As decision-makers struggle to find ways to reduce costs while improving health care delivery, health technology assessments (HTA) provide the evidence required to make better-informed decisions.This is the first book that focuses on the statistical options of HTAs, to fully capture the value of health improvements along with their associated economic consequences. After reading the book, readers will better understand why some health technologies receive regulatory or reimbursement approval while others do not, what can be done to improve the chances of approval, as well as common shortcomings of submissions for drug and device reimbursement.The book begins by contrasting the differences between regulatory approval and reimbursement approval. Next, it reviews the principles and steps for conducting an HTA, including the reasons why different agencies will hTable of ContentsRegulation, Reimbursement and Health Technology Assessment. Requirements and Sources of Data to Complete an HTA. Meta-Analysis. Network Meta-Analysis. Bayesian Methods. Survival Analysis. Costs and Cost of Illness Studies. Health-Related Quality of Life. Missing Data Methods.

Read more less

Book SynopsisStatistical Testing Strategies in the Health Sciences provides a compendium of statistical approaches for decision making, ranging from graphical methods and classical procedures through computationally intensive bootstrap strategies to advanced empirical likelihood techniques. It bridges the gap between theoretical statistical methods and practical procedures applied to the planning and analysis of health-related experiments.The book is organized primarily based on the type of questions to be answered by inference procedures or according to the general type of mathematical derivation. It establishes the theoretical framework for each method, with a substantial amount of chapter notes included for additional reference. It then focuses on the practical application for each concept, providing real-world examples that can be easily implemented using corresponding statistical software code in R and SAS. The book also explains the basic elements and methodsTrade Review"This book covers a wide range of statistical approaches to hypothesis testing for decision-making in various health science research fields. It provides not only refreshing information on many routinely used statistical methods but also a good review of more advanced methods such as empirical likelihood (EL) methods… For clinicians or medical researchers with some training in statistics, many chapters can serve as references. For research statisticians, the book provides important properties and theoretical elaborations for the methods. For pharmaceutical drug trial statisticians in particular, the book on one hand offers a systematic account of many methods and on another hand exposes them to the methods used in some related research fields (e.g., diagnosis identification and testing) that lead one to see the interrelations across such research fields. Throughout the book, the authors transfer the statistical concepts and methods to real-world applications, with emphasis on implementing the methods in R and SAS program code and on interpreting the results…Another great feature of the book is that the authors provide supplemental materials on the evolution of the methodology with additional research notes in each chapter. These give research-oriented statisticians a comprehensive list of references which would be quite helpful for their research. The supplemental materials are also entertaining for the general readers to learn the chronology of statistical theory and methods."—X. Daniel Jia, published in Journal of Biopharmaceutical Statistics, April 2017"With techniques spanning robust statistical methods to more computationally intensive approaches, this book shows how to apply correct and efficient testing mechanisms to various problems encountered in medical and epidemiological studies, including clinical trials."—TLT Magazine, September 2016"This comprehensive book takes the reader from the underpinnings of statistical inference through to cutting-edge modern analytical techniques. Along the way, the authors explore graphical representations of data, a key component of any data analysis; standard procedures such as the t-test and tests for independence; and modern methods, including the bootstrap and empirical likelihood method. The presentation focuses on practical applications interwoven with theoretical rationale, with an emphasis on how to carry out procedures and interpret the results. Numerous software examples (R and SAS) are provided, such that the readers should be able to reproduce plots and other analyses on their own. A wealth of examples from real data sets, web resources, supplemental notes, and plentiful references are provided, which round out the materials."—From the Foreword by Nicole Lazar, Department of Statistics, University of GeorgiaTable of ContentsPreliminaries: Welcome to the Statistical Inference Club: Some Basic Concepts in Experimental Decision Making. Statistical Software: R and SAS. Statistical Graphics. A Brief Ode to Parametric Likelihood. Tests on Means of Continuous Data. Empirical Likelihood. Bayes Factor–Based Test Statistics. The Fundamentals of Receiver Operating Characteristic Curve Analyses. Nonparametric Comparisons of Distributions. Dependence and Independence: Structures, Testing, and Measuring. Goodness-of-Fit Tests (Tests for Normality). Statistical Change-Point Analysis. A Brief Review of Sequential Testing Methods. A Brief Review of Multiple Testing Problems in Clinical Experiments. Some Statistical Procedures for Biomarker Measurements Subject to Instrumental Limitations. Calculating Critical Values and p-Values for Exact Tests. Bootstrap and Permutation Methods. References. Index.

Read more less

Book SynopsisEffectively Assess Intervention Options for Controlling Infectious DiseasesOur experiences with the human immunodeficiency virus (HIV), severe acute respiratory syndrome (SARS), and Ebola virus disease (EVD) remind us of the continuing need to be vigilant against the emergence of new infectious diseases. Mathematical modeling is increasingly used in the management of infectious disease control as a way to assess interventions relatively quickly, cheaply, and safely. Modeling to Inform Infectious Disease Control shows readers how to take advantage of these models when developing strategies to mitigate infectious disease transmission. The book presents a way of modeling as well as modeling results that help to guide the effective management of infectious disease transmission and outbreak response. It discusses the requirements for preventing epidemics and ways to quantify the impact of prevenTrade Review"This book provides an accessible introduction to the use of mathematical models to inform infectious disease management. The core material is designed to be read by someone with a 'modest knowledge of mathematics', possessing the ability to 'interpret an algebraic formula and [understand] what it means to solve an equation'; some additional knowledge of basic statistics is stated as being useful. ... The core material is complemented by more technical supplementary material at the end of each chapter, for readers with greater knowledge of mathematics. Exercises are included in each chapter which support the material and would be suitable for use as part of an introductory course...The language in the book is direct and clear, and the material is well motivated. ... Overall, this book is a valuable resource to those new to infectious disease (stochastic) modelling. It is rather unique in the level of assumed knowledge, the probabilistic foundation (including handling of branching process and stochastic household model results), the provision of tangible and realistic insight into how these models inform public health management, and the integration of data. To achieve this all within just over 200 pages is a great feat." -Joshua V. Ross School of Mathematical Sciences, The University of Adelaide, in Australian & New Zealand Journal of Statistics, 2016 "This new book seeks to fill an important gap in the literature on infectious disease modeling, namely separating the now well-developed mathematical and statistical theory of infectious diseases from its public health application to infectious disease control. Professor Becker bridges the two worlds by presenting a logical succession of simple models that relate to some of the pressing questions arising in outbreak control. The approach is very effective and has resulted in an engaging volume that, in my estimation, will become a classic of the literature and thus a worthy successor to the author's earlier landmark volume on the subject. It will be essential reading for a broad range of scientists working on infectious diseases, notably statisticians, modelers, and epidemiologists with an interest in quantitative methods." -Paddy Farrington, The Open University, UKTable of ContentsIntroduction. Minor outbreaks when infectives are homogeneous. Minor outbreaks in a community of households. Minor outbreaks when individuals differ. Transmission intensity function. Partially effective vaccines. Social distancing. Reducing epidemic size. Dynamics of infection incidence. Using data to inform model choice. Terminology and notation. References. Subject index.

Read more less

Book SynopsisSince the publication of the first edition in 2000, there has been an explosive growth of literature in biopharmaceutical research and development of new medicines. This encyclopedia (1) provides a comprehensive and unified presentation of designs and analyses used at different stages of the drug development process, (2) gives a well-balanced summary of current regulatory requirements, and (3) describes recently developed statistical methods in the pharmaceutical sciences. Features of the Fourth Edition: 1. 78 new and revised entries have been added for a total of 308 chapters and a fourth volume has been added to encompass the increased number of chapters. 2. Revised and updated entries reflect changes and recent developments in regulatory requirements for the drug review/approval process and statistical designs and methodologies. 3. Additional topics include multiple-stage adaptive trial design in clinical research, translational medicine,

Read more less

Book SynopsisBiomechanics applies the laws and techniques of mechanics in the study of biological systems and related phenomena. Biomechanics uses mathematical and computational tools such as model construction of musclo-skeletal system, body fluid circulation, to aid medical diagnosis, therapeutics and surgery planning, designing of prostheses and implants or in tissue engineering. Present book targets specific topics pertaining to the biomechanics of soft tissues. Subjects addressed includes solids and multi-species mixtures as open systems: a continuum mechanics perspective; electro-chemo-mechanical couplings: tissues with a fixed electric charge and growth of biological tissues.Table of ContentsBiomechanical topics in soft tissues. Solids and multi-species mixtures as open systems: a continuum mechanics perspective. Elements of continuum mechanics. Thermodynamic properties of fluids. Multi-species mixtures as thermodynamically open systems. Anisotropic and conewise elasticity. Hyperelasticity, a purely mechanical point of view. Poroelasticity with a single porosity. Viscoelasticity and poro-viscoelasticity. Thermoelasticity and thermo-poroelasticity. Transfers of mass, momentum and energy. Waves in thermoelastic solids and saturated porous media. Electro-chemo-mechanical couplings : tissues with a fixed electric charge. Directional averaging and mechanical properties of fiber-reinforced tissues. Electro-chemo-mechanical couplings. Chemo-mechanical couplings in articular cartilages. Passive transport in the interstitium and circulation: basics. Coupled transportsin tissues endowed with a fixed electric charge. Effects of pH on the transport and mechanical properties of articular cartilages. Finite element analysis of electro-chemo-mechanical couplings. Two lamellar tissues: cornea and annulus fibrosus. Active transport. Growth of biological tissues. Tissue Engineering: overview of biochemical data and mechanical modeling. Growth of soft tissues. Kinematics, formulation and examples. Elastic-growing solids. Thermodynamically consistent growth laws. Elastic-growing mixtures. Solid tumors: biochemical overview and mechanical modeling. Units and physical constants. Bibliography

Read more less

Book SynopsisThe USA Today Bestseller 'The infectious disease expert who predicted the spread of coronavirus' - Daily Mail'Osterholm has produced a sharp, persuasive and urgent manifesto for how the world needs to think differently about natural threats, offering a blueprint for setting priorities and explaining why the infrastructure of global health needs reconfiguring... Deadliest Enemy will help to set the terms of that essential post-coronavirus conversation.' - Financial TimesUnlike natural disasters, whose destruction is concentrated in a limited area over a period of days, and illnesses, which have devastating effects but are limited to individuals and their families, infectious disease has the terrifying power to disrupt everyday life on a global scale, overwhelming public and private resources and bringing trade and transportation to a grinding halt.In today's world, it's easier than ever to move people, animals, and materials around the planet, but the same advances that make modern infrastructure so efficient have made epidemics and even pandemics nearly inevitable. And as outbreaks of COVID-19, Ebola, MERS, and Zika have demonstrated, we are woefully under-prepared to deal with the fallout. So what can - and must - we do in order to protect ourselves from mankind's deadliest enemy?Drawing on the latest medical science, case studies, policy research, and hard-earned epidemiological lessons, Deadliest Enemy explores the resources and programs we need to develop if we are to keep ourselves safe from infectious disease. The authors show how we could wake up to a reality in which many antibiotics no longer cure, bio-terror is a certainty, and the threat of a disastrous influenza or coronavirus pandemic looms ever larger. Only by understanding the challenges we face can we prevent the unthinkable from becoming the inevitable.Deadliest Enemy is high scientific drama, a chronicle of medical mystery and discovery, a reality check and a practical plan of action.Trade ReviewThe infectious disease expert who predicted the spread of coronavirus. * Daily Mail *Osterholm has produced a sharp, persuasive and urgent manifesto for how the world needs to think differently about natural threats, offering a blueprint for setting priorities and explaining why the infrastructure of global health needs reconfiguring... Deadliest Enemy will help to set the terms of that essential post-coronavirus conversation. * Financial Times *A sharp, persuasive and urgent manifesto for how the world needs to think differently about natural threats. * Financial Times *It really feels, in short, like the sort of book that we ought to have been reading this time last year. * The Times *

Read more less

Book SynopsisThe end of the 20th century brought with it a revolution in molecular biology that culminated in advances such as the completion of the human genome. This has brought optimism to the fields of toxicology and environmental health, and the anticipation that molecular biomarkers might soon come of age and have a major impact on human and environmental health. Biomarker research is an area of current interest to scientists in a number of fields that are concerned with environmental exposure to pollutants and environmentally associated disease.Biomarkers of Environmentally Associated Disease: Technologies, Concepts, and Perspectives provides comprehensive coverage of the current status and future prospects of a field that will play a key role in emerging areas of public health and medicine. It focuses on the risk to human and environmental health of exposure to persistent organic pollutants, heavy metals, airborne toxics, environmental estrogens, and other environmental pollutants. This material will aid researchers in understanding, treating, and preventing environmentally induced disease.Validated molecular biomarkers have long been recognized as invaluable tools for identifying and preventing human disease. As biomarkers begin to be applied more widely, it is also important to assure that they are implemented ethically, with attention to the social and legal issues associated with their use. Biomarkers of Environmentally Associated Disease is an outstanding resource providing state-of-the-art information for the fields that encompass molecular biomarkers.Table of ContentsAcknowledgements. Overview. Genomics-Based Biomarkers/Genetic Toxicology Biomarkers. Biomarkers Of Metal Metabolism. Organ & Systems Biomarkers. Biomarkers And Chemical Toxicants. Nanotechniques & Biomarkers.

Read more less

Book SynopsisThis work includes a foreword by Jeffrey Koplan, Vice President, Academic Health Affairs, Emory University, Atlanta, Formerly Director, Centers for Disease Control and Prevention (CDC). This groundbreaking new book blows apart the myths about who is at risk of getting AIDS and shows how these myths are driven by moral and political pressures. It provides an objective, logical, clear, epidemiologically based analysis on the current situation and situates itself firmly at marked variance with the politically correct position of UNAIDS and most AIDS activists. "The AIDS Pandemic" argues that the story of HIV has been distorted by UNAIDS and AIDS activists in order to support the myth of the high potential risk of HIV epidemics spreading into the general population. In the past, most policy makers and members of the public have uncritically accepted UNAIDS' high prevalence estimates and projections when in fact lower HIV prevalence estimates are more accurate. Time, money and resources are being wasted worldwide. This book is full of fresh analysis for all people working in any capacity in HIV/AIDS programmes. It will be invaluable to undergraduate and postgraduate healthcare students, health and social care professionals and the international media. Policy makers and shapers will find the pioneering information crucial to the future of the AIDS strategy. 'For close to a half century, my work as a public health epidemiologist has involved field research, program management, and teaching, mostly on public health surveillance and prevention and control of communicable diseases. [Since 1981] I have been involved virtually full time with the international response to the AIDS pandemic which is without question one of the most severe infectious disease pandemics in modern times. During my public health career that began in the early 1960s, I have always been considered a part of conventional or mainstream medical science. However, since the mid-1990s, I have found myself swimming upstream against mainstream AIDS organisations. I have, during this period, gradually come to the realisation that AIDS programs developed by international agencies and faith based organizations have been and continue to be more socially, politically, and moralistically correct than epidemiologically accurate.' - James Chin, in the Preface. 'Controversy and differing opinions have been hallmarks of the AIDS epidemic since its onset. The scope of the problem, how to identify high risk groups without increasing the burden of stigma, the safety of blood products, the best balance between prevention and treatment, have all been hot issues sometimes dividing the public health community. The passion and conflicts about how to consider and address the AIDS pandemic reflect the huge impact this disease has had globally and its interplay with macro economic, legal, social, political, national security and ethical domains. Vital, provocative, thoughtful, direct, passionate, rational and willing to challenge conventional wisdom. "The AIDS Pandemic" is filled with information, rational arguments and opinions, often intermingled. It is a rare book on epidemiology that puts so much of the author's personality and viewpoints, along with his knowledge and experience, before the reader. The result is a thought-provoking, likely-to-be-controversial, contribution to the AIDS literature that should engage and stimulate the reader.' - Jeffrey Koplan, in the Foreword.Table of ContentsPersonal and professional background. The most probable origin and initial global spread of HIV. A basic primer on HIV infections and AIDS cases (HIV/AIDS). HIV epidemiology and transmission dynamics. Calculation of the reproductive number of HIV and the probability of acquiring an HIV infection in female sex workers and in their male clients in the Philippines. Describing the analogy between factors needed for a forest fire and an HIV epidemic. Understanding HIV/AIDS numbers. EPIMODEL. How credible are HIV/AIDS estimates? HIV/AIDS prevention. Dispelling 'Glorious' HIV/AIDS myths and misconceptions. The most probable past, present, and future of the AIDS pandemic. The International response to the AIDS pandemic.

Read more less

Book SynopsisHealth care needs assessment provides information to plan, negotiate and change services for the better, and to improve health in other ways. The first edition of this series established itself as a key source on health care needs for specific conditions supported by the Department of Health. Now in its second edition it provides vital updates taking into account how health care has moved on and how the structure of the UK's health service has changed. Each of the chapters follows the same structure; each analysing its topic, reviewing the incidence and prevalence, the range of services available, and the effectiveness of those services. It describes the central role and aim of health care needs assessment in the NHS health care reforms and explains the 'epidemiological approach' to needs assessment and its effectiveness. Volume 1 includes diabetes mellitus, renal disease, stroke, lower respiratory disease, coronary heart disease, colorectal cancer, cancer of the lung, osteoarthritis affecting the hip and knee, cataract surgery and groin hernia. Volume 2 includes varicose veins and venous ulcers, benign prostatic hyperplasia, severe mental illness, Alzheimer's disease, alcohol misuse, drug misuse, learning disabilities, community child health services and contraception, induced abortion and fertility services. All health professionals, including policy makers and shapers and those assessing quality of service will find this book an essential resource.Table of ContentsVolume 2. Varicose veins and venous ulcers. Lower urinary tract symptoms and the benign prostrate hyperplasia. Severe mental illness. Alzheimer's disease and other dementias. Alcohol misuse. Drug misuse. Learning disabilities. Community child health services. Contraception, induced abortion and fertility services. Reflections. Conclusions.

Read more less

Book SynopsisWhat lies at the root of the SARS-CoV-2 virus and the worldwide pandemic it has caused, affecting the health and livelihoods of untold millions of people? What are the deeper, spiritual realities behind COVID-19 and the global turmoil it has left in its trail? In an effort to answer these queries and many others put to her at the start of the pandemic, Judith von Halle composed two letters in March 2020, based on her own spiritual-scientific research. Published in this book together with an additional essay, she addresses questions such as: * Which entities stand behind the virus? * How and why does it affect human beings? * What measures can be taken for prevention and therapy? * What does the crisis mean to individuals and what possibilities does it offer for personal development? The author suggests that, apart from the material havoc triggered by coronavirus, the spiritual causes behind it are extremely serious and - if the present pandemic is not to be the first in a series of catastrophes - humanity is called upon to respond in a radically transformative way. In an additional article von Halle tackles the controversial issues relating to government lockdowns and the protest movements that have sprung up in opposition to them. How do these events point to real questions of individual freedom and, most importantly, how do they relate to the central event of our time - an event that, tragically, remains largely unknown? Revealing unexpected perspectives to the COVID-19 pandemic, Judith von Halle asks urgent and difficult questions and offers shattering insights for humanity's further development.Table of ContentsPreface - I. WHAT CAN ANTHROPOSOPHICAL SPIRITUAL SCIENCE CONTRIBUTE TO SARS-COV-2 AND COVID-19 RESEARCH? - The First Letter, Berlin, 22 March 2020 - 'Corona-Pandemic -Aspects and Perspectives' (Newsletter from the Medical Section of the Goetheanum) - About the 'Aspects' - About the 'Perspectives' - At Attempt at a Deeper Consideration of the Coronavirus Pandemic - About the Spiritual Cause of the SARS-CoV-2-Virus - On the Character of Bacteria - On the Character of Viruses - The Way SARS-CoV-2 Spreads - On the Symptoms of the COV-19 Illness - Spiritual Aspects - Commentary on Further Questions - II. QUESTIONS AND ANSWERS RELATING TO ESOTERIC SUPPORT FOR WORK IN THE BRANCH - The Second Letter, Berlin, 22 March 2020 - Publisher's Foreword - Overcoming Fear - How Intensifying Meditation Can be Helpful in These Times - What Does It Mean When People Can No Longer Meet? - Starting Point: Consistently Practise Soul Exercises - Suggestions for Spiritual Support for the Ongoing Work in the Branch - III. THE GREAT DIVERSIONARY MANOEUVRE - The Awareness of the Central Event of our Time, the Perception of the Christ Entity as an Etheric Phenomenon - Everything is Upside Down - Appendix: The Eight Soul Exercises by Rudolf Steiner - Notes

Read more less

Book Synopsis

Read more less

Book SynopsisThe developing countries are recelvmg generous Government Offices, and commercial organizations attention from experts, officials and academics drawn deserve our sincere thanks for their attention to our from a wide spectrum of specialist interests. Some of this many enquiries. In particular, we would like to thank effort is directed towards a solution of several of the the officials of the Planning Board and the Central world's most pressing problems, including ill-health, Statistical Office, Kuwait Municipality, University of under-nourishment, and rapid population growth, but Kuwait, and the Kuwait Oil Company. The following other workers are more concerned with the less immedi- individuals deserve our special thanks: Mr. Ahmad al- ate but nonetheless very significant theoretical aspects Duaij, Mr. Fouad al Hussaini, Mr. Hamid Shwaib, Mr. of the developing countries. This book is an attempt to Abdulaziz aI-Hamdan, Mr. Fouad Haddad, Mr. Ahmad bridge the gap between these two approaches. al-Haj, Mr. Marwan 'Adra', Mr. Muhammad Sukhon, At this present juncture in time we are faced with Professor Abdul Fattah Ismail, Professor Dawlat Sadiq, the realization that the experience of Europe or North Professor Muhammad Mutwalli, Dr. Muhammad Shar- nubi, His Excellency Ibrahim Shatti, Dr. Noel Brehony, America may be of limited assistance in the interpretation Professor W. B. Fisher, Dr. John Brebner, Dr. Alan of current trends in the developing world. Not only is Horan, Mrs.Table of ContentsThe relation of Kuwait’s development to Europe and Far East.- Discovery of oil reserves outside the Middle East.- Arab nationalism.- Great Britain’s responsibility.- Inapplicability of laws and generalizations of developed world.- General lessons of value to others.- Kuwait a testing ground.- 1. Urbanization and Population Growth in the Middle East.- 1. Definitions.- General statements on nature and causes of urbanization.- Historical connections.- Development of civilisations.- Technical innovations.- Sources of labour.- Population increase, food supplies, general educational advances.- 2. Middle East Urbanization: Extent and Special Characteristics.- United Nations’s statistics.- 3. Levels of Urbanization in the Middle East.- 4. Elements Peculiar to the Urbanization of the Middle East.- Social and political urbanization.- Defence role.- Religion.- Oil.- Investment capital.- Israel.- Foreign aid.- 5. Conclusion.- II. The Urbanization of Kuwait. Prosperity alternating with hardship.- 1. The Environment. Physical geography.- a) Summer.- b) Winter.- c) Daily weather.- 2. Water Resources.- a) Occurrence.- b) Development.- 3. Power.- 4. Agriculture.- a) Farmers.- b) Nomads.- 5. Fishing.- a) Pearling.- b) Fishing.- 6. Mineral Resources Industries.- Industries.- Distribution of labour force.- Restriction of economic opportunity.- III. The Early History of Kuwait.- IV. The Economic Development of Kuwait.- V. Population Growth in Kuwait. Twelve hundred per cent increase in 60 years.- 1. Introduction.- Preponderance of non-Kuwaitis.- Nationality law.- Duality of national life.- 2. Population Expansion by Immigration.- a) War-time immigration.- b) Post-war immigration.- c) Factors involved in immigration.- d) The Alien population 1957–1965.- aa) Sex ratios.- bb) Age structure.- e) Permanency of migration to Kuwait.- f) Arrivals after 1965.- 3. Population Expansion by Natural Increase. Introduction.- a) Vital statistics in Kuwait.- b) Natality, mortality and the population cycle.- c) Health facilities in Kuwait.- aa) Growth.- bb) Effect.- d) Age structure of the Kuwait population.- aa) The Kuwaitis.- bb) The Non-Kuwaitis.- e) Natality and fertility.- aa) Kuwaitis.- bb) Non-Kuwaitis.- f) Mortality.- aa) Kuwaitis.- bb) Non — Kuwaitis.- 4. Conclusions - Natural Increase.- a) Kuwaitis.- b) Non-Kuwaitis.- VI. The Ecology of Daily Life.- A. The Rural Community.- Agriculture.- Water resources.- Pastoral nomadism.- Cultural legacy of the Badu.- Religion, fasts and feasts.- Emphasis on kinship.- Hospitality, manners and modes.- B. The Urban Community.- Post-War Expansion of the Built up Area.- 1. Kuwait City Before Oil Discoveries.- a) Extent.- b) Internal characteristics and differentiation.- 2. Kuwait City after the Discovery of Oil.- Rising revenues and immigration.- 3. The Government Land Purchase Scheme.- 4. Planning and Urban Expansion.- a) The 1952 plan.- b) Physical expansion of the city structure.- c) Subsequent plans.- 5. The Contemporary City.- a) The Old City.- b) The Kuwait neighbourhoods.- c) Hawalli and Salimiya.- d) Abruq Khaitan and Farwaniya.- e) Ahmadi and Fahahil.- C. Population Distribution and Density within the Urban Areas.- 1. Changing Patterns of Population Distribution.- a) Before the first census.- b) Effects of oil discoveries.- c) Population distribution in 1957.- d) Population distribution in 1965.- D. Population Composition and Social Areas within Kuwait.- 1. “Western” and “non-Western” Cities.- 2. Land Use and Urban Ecology.- a) Methods.- b) Selection of variables.- 3. The Distribution of Individual Variables.- a) Kuwaitis and non-Kuwaitis.- b) Illiterates.- c) Employees in construction.- d) Professional and temnical workers.- e) Administrative workers.- 4. The Analysis of Groups of Variables.- a) Method.- b) Variables.- 5. The Factors: Their Composition and Distribution.- a) Factor composition.- b) The distribution of factors throughout Kuwait.- 6. The Geographic Distribution of Individual Factors.- 7. Combinations of all 3 Factors.- a) Group 1.- b) Group 2.- c) Group 3.- d) Group 4.- 8. Factor Analysis and the Structure of Kuwait City.- 9. Social Areas in Kuwait City.- a) The Old City and other areas of immigrant invasion.- b) Areas under construction with low-status immigrants.- c) Strongly Kuwaiti areas.- 10. International Parallels.- 11. Conclusion.- VII. Health and Disease.- 1. Introduction.- a) Pseudo-urbanization.- b) The health of the Badu.- c) Effects of urbanization.- d) Integration of planning for social and environmental manges.- e) The importance of integrating disciplines beyond fringe of medicine.- f) Adaptation of the individual to meet the new stresses.- g) Alterations in disease patterns.- h) Definition of Medical Geography.- 2. Specific Problems of Kuwait.- a) Training for responsibility.- b) Infectious disease.- c) Infant gastro-enteritis.- d) Kuwait as an epidemiological listening post.- e) Genetic disease.- f) Environmental influences.- g) Blindness.- VIII. Preventive Medicine in Kuwait.- 1. Preventive Medical Service.- a) Establishment: urban planning: water supplies; killing of animals.- b) Structure of Ministry of Public Health.- c) Growth of services.- d) Communications.- e) Health education.- f) Inspection of buildings and regulations.- g) Private industrially financed medical services of the oil companies.- 2. Infectious Diseases.- a) Comparison with other geographic areas.- b) Leprosy.- c) Hepatitis.- d) Rabies.- e) Malaria.- f) Poliomyelitis.- g) Bacillary Dysentery.- h) Amoebic Dysentery.- i) Worms.- j) Schistosomiasis.- 3. School Medical Services.- a) School population.- b) Development of service.- c) Epidemiology.- d) Nutrition.- IX. Treatment Services.- 1. Traditional Medicine.- a) Badu practices.- b) Branding.- c) The history of Arabian medicine.- d) The Nestorians and Persians.- 2. Modern Treatment Services.- a) European influence in the Gulf.- b) The Political Agency and the American Mission.- c) The Government and oil companies.- d) Professional medical associations.- e) Medical facilities and services.- f) Laboratory services.- g) Tuberculosis diagnostic laboratory.- h) Blood transfusion services.- i) Relative paucity of published clinical eports until 1968.- X. Trauma, Temperance, Tuberculosis and Toxoplasmosis.- 1. Trauma.- a) War and wounds.- The last battle of Jahra 1920.- Dr. Mylrea’s account.- b) Deaths and accidents on the roads.- c) Statistics.- Industrial and domestic accidents.- 2. Temperance.- Religious law and alcohol.- Different countries’ experience.- Prohibition in Kuwait.- The position for non-Moslems.- Illegal distilling.- Smuggling.- Effects of alcohol intoxication.- 3. Tuberculosis.- Experience of the Badu.- Infection in older people.- Population sampling.- Treatment facilities.- Visit of WHO in 1961.- B.C.G. vaccination.- Conversion rates.- Non -pulmonary tuberculosis.- 4. Toxoplasmosis.- Epidemiology elsewhere.- The study in Kuwait.- Clinical findings.- Significance of endemicity in local sheep and goats.- XI. Psychiatric Illness.- The pattern in Kuwait.- Traditional practices.- Hospital facilities.- Incidence of disease.- Use of drugs.- Sexual deviation and homosexuality.- Emancipation of women and psychoneurotic effects.- The effects of industrialisation.- XII. The Haemoglobinopathies.- 1. First Recognition in Kuwait.- World distribution.- Source of Kuwait’s population; migrations.- 2. Sickle-Cell Anaemia.- 3. Thalassaemia: definition.- Clinical and laboratory studies: treatment.- 4. Glucose-6-Phosphate Dehydrogenase Deficiency of the Red Blood Cells.- XIII. Heat Illness and Desert Survival.- Comparative physiology in man and animals.- The Badu: conservation of energy, comfort and discipline.- Heat gain and loss.- Investigations in Kuwait, and elsewhere on the Badu.- Types of heat illness.- Heat-illness among oil tanker crews.- Heat-stroke in Kuwait.- Steps taken to combat effects of heat stroke.- Factors affecting heat control.- XIV. Occupational Health.- 1. Epidemiology.- Development of government and oil company services.- Establishment of standards.- Liaison with I.L.O. and other countries.- Education of doctors and other health workers.- 2. Petroleum and its Hazards to Health in Kuwait.- The history of petroleum and its development.- Use and destination of Kuwait products.- Use of natural gas.- Medical uses of petroleum.- Hazards of petroleum manufacturing to workers and public; explosive and toxic.- Additive effects of sun and petroleum on skin.- Possible long-term carcinogenic effects on various body organs.- 3. Secondary Industries.- Development and pattern.- Asbestos.- Training for industry.- Health education.- XV. Air Pollution.- The desert air, sand, dusts, spores and fungi.- Cigarette.- Urban planning.- Industrial air pollution.- Petroleum products, combustion.- Legislation.- WHO advice.- Investigations of pollen production, Prosopis spicigera.- Air-conditioning of houses.- Atmospheric ionisation.- XVI. Conclusion.- Comparision of urbanization today with nineteenth century Europe.- Kuwait’s anomalous development in Eastern Arabia.- The intrusion of “foreigners” and internal schisms.- Disease as a measure of the problem.- The danger of dualism.- The lessons of enlightened colonialism.- Kuwait’s limited man-power pool.- Diversification of trade and industry.- Oil as a political weapon.- Need for an understanding of ecology by Kuwait’s children.- The problems of citizenship.- The importance of a “cross-cultural” outlook.- Kuwait as a study of enlightened development.- References.- Illustrations.

Read more less

Book SynopsisEinblicke in einer verborgene WeltViren sind Grenzgänger des Lebens. Mikroskopisch klein, als Krankheitserreger gefürchtet, doch in ihrer Vielfalt und in ihrer Bedeutung für die biologischen Netzwerke auf der Erde und für die Evolution des Lebens erst ansatzweise verstanden - und immer wieder für Überraschungen gut. Viren sind Opportunisten, die oft geduldig auf ihre Chance warten - in Ruhestadien oder eingebettet in das Erbgut ihrer Wirte -, und Meister der Anpassung. Ihre Vermehrungsstrategien und Übertragungsmechanismen sind so vielfältig wie ihre Erscheinungsformen. Die meisten Viren sind "nur" Nucleinsäuren in einer Proteinhülle, aber sie kapern Pflanzen-, Tier- und Bakterienzellen, nisten sich dort langfristig ein oder übernehmen unmittelbar die genetische Kontrolle. Dieser Band eröffnet einen faszinierenden Blick auf das ganze Panorama dieser Lebenskünstler, die wir gewöhnlich als Feinde betrachten, die aber auch Helfer sein können. Nach einer Einführung in die Grundlagen der Virologie - was genau sind Viren, woraus bestehen sie, wie sehen ihre Lebenszyklen aus, welche Evolutionspfade haben sie beschritten? - liefern 101 Porträts detaillierte Einblicke in die besonderen Eigenschaften und Fähigkeiten einzelner Virustypen, vom Grippeerreger bis zum Bakteriophagen T4, vom Tabakmosaikvirus bis zu den gefürchteten Ebola-, Zika- und Dengue-Viren.Trade Review“... Basisinformationen zum jeweiligen Virus vermittelt eine kurze, aber prägnante und äußerst verständliche Beschreibung. Übersichtliche und einprägsame Zeichnungen erleichtern das Verständnis bestimmter Besonderheiten. Zahlreiche Aufnahmen von Viren lassen sie bei allem Schrecken, den sie verursachen können, in ganz neuem Bild erscheinen.” (Dr. Thomas Patzelt, Hehlen, in: Rundschau für Fleischhygiene und Lebensmittelüberwachung RLF, Jg. 73, Februar 2021)Table of ContentsViren des Menschen.- Viren der Wirbeltiere.- Viren der Pflanzen.- Viren der Wirbellosen.- Viren der Pilze und Protisten.- Viren der Bakterien und Archaeen.

Read more less

Book Synopsis

Read more less

Book SynopsisOriginating in Cuba in 1897, yellow fever shuttered businesses, paralyzed trade, and caused tens of thousand of people living in the southern United States to abandon their homes and flee for their lives. This title uncovers how the devastating power of this virus profoundly shaped the relationship between the two countries.Trade Review"This elegant study not only reshapes our understandings of U.S.-Cuban relations but also forces us to rethink the broader history of U.S. public health interventions all over the world. It is a model for doing transnational history." - Paul Sutter, University of Colorado"

Read more less

Book SynopsisPresents an extended case study of the 20th-century AIDS epidemic and the cultural circumstances from which it emerged. The book brings together anthropology, demography and epidemiology to explain how the Chagga people of Tanzania in Africa experience AIDS.

Read more less

Book SynopsisThe media constantly bombard us with news of the health hazards that lurk in our everyday lives. But, many of these hazards, even some that provoke regulatory action, have been greatly overblown. This book examines the forces that contribute to health scares and economic, political, and psychological consequences of their "social amplification."Trade ReviewThe book can engage and enlighten regarding the complex context in which known and suspected health risks are identified, explored, and acted on. -- Barbara Gastel, M.D., M.P.H The New England Journal of Medicine A strong, valuable corrective to public understanding of the debate of environmental hazards... Highly Recommended. CHOICE Reading and reflecting on the thesis of this book can only help epidemiologists be more aware of our place in society and thus be more effective contributors. -- David A. Savitz American Journal of Epidemiology With clarity and dispassion, Geoffrey C. Kabat challenges widespread beliefs that secondhand smoke, low levels of radon, and other ostensible environmental nemeses are certain killers. In making his case, Kabat draws extensively on scientific evidence while shunning rhetoric and political posturing. The result is an admirable search for scientific truth amid a sea of conflicting and often uninformed opinions. -- Leonard Cole, Rutgers University Geoffrey C. Kabat, a respected epidemiologist, provides an insider's account of how a number of ostensible health hazards have been blown out of proportion. While we face a daily barrage of health scares, Kabat cuts through the confusion and provides a lucid and rigorous rationale for rejecting much of the fear culture that permeates our society. -- Shelly Ungar, University of Toronto This book does an exceptionally good job, first by putting epidemiology within the context of public health and then by explaining key terms, concepts, and methods. It provides a penetrating treatment of a difficult and complex subject in a readily understandable way. -- Steven D. Stellman, Mailman School of Public Health, Columbia University "Kabat, who wrote Hyping Health Risks--a fascinating and detailed examination of how we fell for certain, illusory environmental hazards--is possibly the only epidemiologist in the world to have also published a book on Dostoyevsky (he got a Ph.D in Russian and comparative literature from Columbia before switching tracks). And the background in literary analysis and theory adds a crucial ability to explain why we, as a society, are prone to turning hypothetical risks into "social facts." The upshot is that most public alarms about health risks dispense with the tools required to make sense of the alarm--and we end up with "disembodied findings" and ideology." -- Trevor Butterworth Forbes "Health scares come and go, but they often have a tenuous scientific basis. Kabat, a cancer epidemiologist, systematically rips through cancer alerts that overrode scientific rigor in recent decades. In so doing, he dispels the dubious science underlying the scares and explains how public confusion can come about. ... He extends his critique to debates linking radon gas exposure and secondhand cigarette smoke exposure to lung cancer. Those chapters will ruffle some feathers, but Kabat is unafraid of controversy." -- Nathan Seppa ScienceNews rich and valuable... -- Trevor Butterworth Forbes.comTable of ContentsPreface Abbreviations 1. introduction: Toward a Sociology of Health Hazards in Daily Life 2. Epidemiology: Its Uses, Strengths, and Limitations 3. Does the Environment Cause Breast Cancer? 4. Electromagnetic Fields: The Rise and Fall of a "Pervasive Threat" 5. The Science and Politics of Residential Radon 6. The Controversy Over Passive Smoking: A Casualty of the "Tobacco Wars" 7. Conclusion Appendix A: List of Interviews Appendix B: How Findings Can Be Reported in a Way That Puts Them in Perspective Notes Glossary Bibliography Credits Index

Read more less

Book SynopsisTrade ReviewThe book can engage and enlighten regarding the complex context in which known and suspected health risks are identified, explored, and acted on. -- Barbara Gastel, M.D., M.P.H The New England Journal of Medicine A strong, valuable corrective to public understanding of the debate of environmental hazards... Highly Recommended. CHOICE Reading and reflecting on the thesis of this book can only help epidemiologists be more aware of our place in society and thus be more effective contributors. -- David A. Savitz American Journal of Epidemiology With clarity and dispassion, Geoffrey C. Kabat challenges widespread beliefs that secondhand smoke, low levels of radon, and other ostensible environmental nemeses are certain killers. In making his case, Kabat draws extensively on scientific evidence while shunning rhetoric and political posturing. The result is an admirable search for scientific truth amid a sea of conflicting and often uninformed opinions. -- Leonard Cole, Rutgers University Geoffrey C. Kabat, a respected epidemiologist, provides an insider's account of how a number of ostensible health hazards have been blown out of proportion. While we face a daily barrage of health scares, Kabat cuts through the confusion and provides a lucid and rigorous rationale for rejecting much of the fear culture that permeates our society. -- Shelly Ungar, University of Toronto This book does an exceptionally good job, first by putting epidemiology within the context of public health and then by explaining key terms, concepts, and methods. It provides a penetrating treatment of a difficult and complex subject in a readily understandable way. -- Steven D. Stellman, Mailman School of Public Health, Columbia University "Kabat, who wrote Hyping Health Risks--a fascinating and detailed examination of how we fell for certain, illusory environmental hazards--is possibly the only epidemiologist in the world to have also published a book on Dostoyevsky (he got a Ph.D in Russian and comparative literature from Columbia before switching tracks). And the background in literary analysis and theory adds a crucial ability to explain why we, as a society, are prone to turning hypothetical risks into "social facts." The upshot is that most public alarms about health risks dispense with the tools required to make sense of the alarm--and we end up with "disembodied findings" and ideology." -- Trevor Butterworth Forbes "Health scares come and go, but they often have a tenuous scientific basis. Kabat, a cancer epidemiologist, systematically rips through cancer alerts that overrode scientific rigor in recent decades. In so doing, he dispels the dubious science underlying the scares and explains how public confusion can come about. ... He extends his critique to debates linking radon gas exposure and secondhand cigarette smoke exposure to lung cancer. Those chapters will ruffle some feathers, but Kabat is unafraid of controversy." -- Nathan Seppa ScienceNews rich and valuable... -- Trevor Butterworth Forbes.comTable of ContentsPreface Abbreviations 1. introduction: Toward a Sociology of Health Hazards in Daily Life 2. Epidemiology: Its Uses, Strengths, and Limitations 3. Does the Environment Cause Breast Cancer? 4. Electromagnetic Fields: The Rise and Fall of a "Pervasive Threat" 5. The Science and Politics of Residential Radon 6. The Controversy Over Passive Smoking: A Casualty of the "Tobacco Wars" 7. Conclusion Appendix A: List of Interviews Appendix B: How Findings Can Be Reported in a Way That Puts Them in Perspective Notes Glossary Bibliography Credits Index

Read more less

Book SynopsisIn The Alchemy of Disease, John Whysner offers an accessible and compelling history of toxicology and its key findings. He details the experiments and discoveries that revealed the causal connections between chemical exposures and diseases.Trade ReviewThe field of toxicology has become increasingly sophisticated as our knowledge of biology continues to evolve. As a scientist, it is enjoyable to read how John Whysner presents the information, and I have no doubt that the general public and students will find it equally enjoyable and informative. -- Samuel M. Cohen, Havlik-Wall Professor of Oncology, University of Nebraska Medical CenterI often tell students in the biological sciences that the best way to learn about a topic is not just to learn what knowledge has been discovered, but rather how the discoveries were made. Whysner’s scholarly yet reader-friendly book reads like a series of fascinating stories derived from his lifetime of experience in the world of toxicology and public health, and what a storyteller he is! The book shows him to be a remarkable science historian as each link between chemical exposures and human diseases is placed in a captivating historical context. The extent to which Whysner has been intimately involved in major discoveries is absolutely mind-boggling. -- Joseph H. Graziano, Mailman School of Public Health, Columbia UniversityWhysner provides an honest evaluation of the science of toxicology, engaging readers with fascinating, well-paced narratives of subjects such as chronic arsenic poisoning. -- Katherine Watson, Oxford Brookes UniversityWhysner's book is a valuable addition to the history of toxicology and allied fields, as it benefits from the institutional knowledge of a professional working in the field of toxicology for five decades. The author brings to light technical aspects of the science that some may not be aware of, especially concepts of risk assessment, dose response, and links between cancer rates and the reality of the state of the science. -- Dale A. Stirling, Consultant in Environmental & Public Health History and author of The Nanotechnology Revolution: A Global Bibliographic Perspective and A Bibliographic Guide to North American Industry: History, Health & Hazardous WasteWhysner ... delivers an illuminating overview of the history of toxicology. Serious students of medical history will appreciate this detailed, historical account of toxicology’s contributions to better health. * Publisher's Weekly *We all have only so much time on this Earth and so much to learn. This fine book presents an efficient and highly enjoyable way to learn the principles and history of the monumental subject of toxicology. -- Judge Lawrence P. Riff * Los Angeles Daily Journal *Table of ContentsAcknowledgmentsIntroductionPart I: Why Do We Need Toxicology?1. Cancer Clusters: Truth Can Be Obscure2. Death from Arsenic and Venoms: Truth Can Be Obvious3. Paracelsus: The Alchemist at Work4. Mining and the Beginnings of Occupational Medicine5. The Chemical Age6. The Bioassay BoomPart II: How Do We Study Toxicology, and What Have We Learned?7. Lead: A Heavy Metal Weighing Down the Brain8. Rachel Carson: Silent Spring Is Now Noisy Summer9. The Study of Cancer10. How Are Carcinogens Made?11. Some Carcinogens Directly Affect Genes12. Cancer Caused by Irritation13. Cigarette Smoking: Black, Tarry Lungs14. What Causes Cancer?Part III: How Do We Use Toxicology?15. Protecting Workers from Chemical Diseases16. The Importance of Having a Good Name17. Can We Accurately Regulate Chemicals?18. The Dose Makes the Poison19. Are We Ready to Clean Up the Mess?20. Legal Battles21. The Toxicology of WarPart IV: The Unfinished Business of Toxicology22. Opiates and Politics23. The Toxicology of Climate Change24. Animal Models for Human Disease25. Are Animal Cancer Bioassays Reliable?26. Hormone Mimics and Disrupters27. Building Better Tools for Testing28. An Ounce of Prevention Is Worth a Pound of CureNotesIndex

Read more less

Book SynopsisTrade ReviewFrom the 1943 reviews:"This book is more than a compendium of data and references from the Old Testament theory of pestilence as a punishment for sin, through the days of demons, miasms, and germs, down to the streamlined concepts of the virus diseases and the new views concerning aerial dissemination of infection. It is an interesting and highly instructive story, rich with the author's interpretations of knowledge regarding the modes and channels of disease spread." —American Journal of Public Health"[This book] will give medical historians matter for discussion . . . the book is for them, really, and for the medical student, who will find in these pages, perhaps for the first time, why the best minds in medicine so delight in the history of its stumbling progress . . . A book nobly concieved, nobly planned, and beautifully written." —Commonweal

Read more less

Book SynopsisTrade Review"Snowden's study...is a remarkable piece of historical work. Original, crystal-clear, analytical and passionate, Snowden...takes us to areas historians have rarely visited before. ... This magnificent study, beautifully written and impeccably documented, deserves an audience beyond specialists in history, or in Italy." - John Foot, The GuardianThe Guardian Book of the Week - Saturday 8th April 2006"In The Conquest of Malaria, Snowden traces the early advances, the setbacks of world wars and Fascist dictatorship, and the final victory against malaria after World War II. . . . Comprehensive and enlightening, The Conquest of Malaria also offers important lessons of today's global malaria emergency."—Italian Tribune“Frank Snowden has drawn on neglected Italian sources to produce a detailed account of the protracted struggle to bring malaria under control in Italy. The Conquest of Malaria is an important contribution to the malaria literature. … [An] excellent book…” - Brian Greenwood, Nature"Frank Snowdon's excellent book provides an insightful and illuminating account of how one nation—Italy—undertook the first national campaign to eradicate this debilitating disease. More importantly, The Conquest of Malaria serves as a timely warning to those who advocate simple technological quick fixes to what was (and still is) a complex environmental, social, economic, and political problem."—Andrea Rusnock, IsisWinner of the 2006 Helen and Howard R. Marraro Prize given by the American Historical AssociationWinner of the 2008 Welch Medal, given by the American Association for the History of Medicine.Winner of the 2007 Malaria Award for Book of the Year given by Malaria Foundation International"With this book, Snowden achieves two difficult goals. He demonstrates how important malaria was to the political and social history of Italy to the mid-twentieth century, an aspect of the country’s course underappreciated by its historians. Perhaps more importantly, he has crafted a marvelously detailed case study in the control of malaria, that shows how closely intertwined are the environmental, medical, social and political features of a landscape that nurtures the disease. Whether describing the temporary Fascist victory over malaria in the Pontine Marshes or the deliberate creation of malarial epidemics by retreating Nazis, Snowden’s lively account convinces the reader that as malaria goes, so goes Italy. This is a first rate, valuable book that belongs on the shelf of historian and malariologist alike."—Dr. Margaret Humphreys, Professor of History, Duke University"Frank Snowden's research on Italy's battle against malaria combines a mastery of the scientific literature with a profound understanding of the laws of motion of Italian society and politics."—John Dickie, author of Cosa Nostra: A History of the Italian Mafia“Frank Snowden’s study of the scourge and final eradication of malaria in Italy is a masterpiece. Rigorous, passionate, and highly original, it deserves a wide audience amongst historians and students.”—John Foot, reader in Modern Italian History, Department of Italian, University College London"A highly original and authoritative reconstruction of Italy's historic and sometimes tragic battle with malaria; in its historical sweep, this book brilliantly conceptualizes disease within a political landscape that includes socialists, liberals, feminists, and fascists. A model for research on the history of medicine."—Mary Gibson, City University of New York

Read more less

Book SynopsisA spine-chilling saga of virulent racism, human folly and the ultimate triumph of scientific progress.Trade Review"David K. Randall has created a meticulously researched history that unfolds like a thriller. I raced through this book in two days (horribly, the span of time it took bubonic plague to fell a victim). The unlikely heroes—bacteriologists and public health officers with long, flowing beards—battle villains most vile: racism, rotten politics, disregard for science, and Yersinia pestis. Black Death at the Golden Gate is both a page-turner and a cautionary tale: Those villains still lurk." -- Mary Roach"Randall’s account is pacy and gripping. And his examination of the conflicts, prejudices and priorities involved make for sober reading in a world where Ebola clinics are being torched and anti-vaccination movements threaten a resurgence in diseases such as measles." -- Nature

Read more less

Book SynopsisThe Epidemiology of Diabetes Mellitus provides a unique, overall assessment of diabetes prevalence with detailed discussion of the impact of the disease in all geographic regions, including Africa, South-East Asia, India, China, and the Caribbean and Pacific Islands.Trade Review"Highly referenced. Recommended to all diabetologists and epidemiologists" (Pediatric Endocrinology, May 2009)Table of ContentsAbout the Editors. Contributors. Foreword. Acknowledgments. 1: Introduction (Jean-Marie Eko´e, Marian Rewers, Rhys Williams and Paul Z. Zimmet). 2: The Clinical Syndrome and the Biochemical Definition (Jean-Marie Eko´e, Paul Z. Zimmet and Jean-Francois Yale). 3: Diagnosis and Classification (Jean-Marie. Eko´e and Paul Z. Zimmet). 4: Epidemiology of Metabolic Syndrome (Dianna J. Magliano, Adrian Cameron, Jonathan E. Shaw and Paul Z. Zimmet). 5: Obesity and Diabetes (Rachel Huxley, Abdullah Omari and Ian D. Caterson). 6: Methodology for Physical Activity Assessment (Kristi L. Storti, Edward W. Gregg and Andrea M. Kriska). 7: Epidemiology of Nutrition and Diabetes Mellitus: Etiology and Environmental Factors (Jim Mann and Monika Toeller). 8: Genetic Epidemiology of Type 2 Diabetes (Leif Groop, Valeriya Lyssenko, Charlotte Ling and Marju Orho-Melander). 9: Epidemiologic Aspects of Type 2 Diabetes Mellitus in Europe (Harry Keen). 10: The Burden of Diabetes and its Complications in theMiddle East and Eastern Mediterranean Region (Imad M. El-Kebbi and Michael M. Engelgau). 11: Epidemiology of Diabetes in Africa (Ayesha A. Motala, Mahomed A. K. Omar and Fraser J. Pirie). 12: Epidemiology of Diabetes Mellitus in Latin America (La´ercio J. Franco and Sandra R. G. Ferreira). 13: Diabetes in the Caribbean . . . an Epidemiological Review! (Errol Morrison and Dalip Ragoobirsingh). 14: Japan (Naoko Tajima). 15: Epidemiology of Diabetes Mellitus in China (Juliana C. N. Chan and Clive S. Cockram). 16: Epidemiology of Diabetes in South East Asia (Ambady Ramachandran and Chamukuttan Snehalatha). 17: The Epidemiology of Diabetes in Pacific Island Populations (Stephen Colagiuri, Taniela Palu, Satupaitea Viali, Zafiml Hussain and Ruth Colagiuri). 18: Epidemiology of Type 2 Diabetes in North America (Linda S. Geiss, Jing Wang, Edward W. Gregg and Michael M. Engelgau). 19: Non-Caucasian North American Populations: Native Americans (Meda E. Pavkov, K. M. Venkat Narayan, Robert G. Nelson, Robert L. Hanson and William C. Knowler). 20: Epidemiology of Type 2 Diabetes in Hispanic North Americans (Judith Baxter and Richard F. Hamman). 21: Non-Caucasian North American Populations: African Americans (Mary A. Banerji and Harold Lebovitz). 22: Epidemiology of Diabetes in Asian North Americans (Marguerite J. McNeely and Wilfred Y. Fujimoto). 23: Epidemiology of Type 2 Diabetes in Children and Adolescents (Jonathan E. Shaw and Dana M. Dabelea). 24: Global Epidemiology of Type 1 Diabetes (Lars C. Stene, Jaakko Tuomilehto and Marian Rewers). 25: Epidemiology of Childhood Diabetes Mellitus in Non-Caucasian Populations (Rebecca B. Lipton). 26: Genetic Epidemiology of Type 1 Diabetes Mellitus (Kirsten O. Kyvik and Anders Green). 27: Recent Trends in Screening and Prevention of Type 1 Diabetes (Marian Rewers). 28: Non pharmacological Prevention of Type 2 Diabetes (Jaakko Tuomilehto). 29: Pharmacological Prevention of Type 2 Diabetes (Andr´e J. Scheen). 30: The Epidemiology of Eye Diseases in Diabetes (Tien Y. Wong and Ron Klein). 31: The Epidemiology of Diabetic Kidney Disease )Anne T. Reutens, Louise Prentice and Robert C. Atkins). 32: Epidemiology of Large-vessel Disease in Diabetes: Coronary Heart Disease and Stroke (Elizabeth Barrett-Connor). 33: The Epidemiology of Peripheral Vascular Disease (Nalini Singh, Stephanie Wheeler and Edward J. Boyko). 34: Epidemiology of Diabetic Neuropathy (Andrew J. M. Boulton). 35: Epidemiology of Acute Complications: Diabetic Ketoacidosis, Hyperglycemic Hyperosmolar State and Hypoglycemia (Alberta B. Rewers). 36: Mortality and Life Expectancy Associated with Diabetes (Elizabeth L. M. Barr, Paul Z. Zimmet and Jonathan E. Shaw). 37: Economic Costs (Rhys Williams and Thomas J. Songer). 38: Clinical Practice Guidelines: A Global Perspective (Barbara Currie, Ehud Ur and Thomas Ransom). 39: Antipsychotic Therapies and Glucose Dysregulation in the Mental Illness Population (Gilbert L’Italien and John Newcomer). 40: Diabetes, Insulin Resistance and Glucose Metabolism in HIV Infection and its Treatment (Kathy Samaras and Don J. Chisholm). Index.

Read more less

Book Synopsis* This book provides an authoritative account of Bayesian methodology, from its most basic elements to its practical implementations, with an emphasis on healthcare techniques. * Contains introductory explanations of Bayesian principles common to all areas.Trade Review“In conclusion, we consider the book by Lesaffre and Lawson a noteworthy contribution to the dissemination of Bayesian methods, and a good manual of reference for many common and some specialized applications in biomedical research. The great variety of examples and topics covered offers both advantages and disadvantages. Some parts might be too specialized for statistics students, but lecturers and applied statisticians will benefit a lot from the authors’ wealth of experience.” (Biometrical Journal, 15 July 2013) “The book Bayesian Biostatisticsby Lesaffre and Lawson, is a welcoming addition to this important area of research in biostatistical applications. For example, in the area of clinical trials, Bayesian methods provide flexibility and benefits for incorporating historical data with current data and then using the resulting posterior to make probability statements for different outcomes”.(Journal of Biopharmaceutical Statistics, 1 January 2013) Table of ContentsPreface xiii Notation, terminology and some guidance for reading the book xvii Part I Basic Concepts in Bayesian Methods 1 Modes of statistical inference 3 1.1 The frequentist approach: A critical reflection 4 1.1.1 The classical statistical approach 4 1.1.2 The P-value as a measure of evidence 5 1.1.3 The confidence interval as a measure of evidence 8 1.1.4 An historical note on the two frequentist paradigms∗ 8 1.2 Statistical inference based on the likelihood function 10 1.2.1 The likelihood function 10 1.2.2 The likelihood principles 11 1.3 The Bayesian approach: Some basic ideas 14 1.3.1 Introduction 14 1.3.2 Bayes theorem – discrete version for simple events 15 1.4 Outlook 18 Exercises 19 2 Bayes theorem: Computing the posterior distribution 20 2.1 Introduction 20 2.2 Bayes theorem – the binary version 20 2.3 Probability in a Bayesian context 21 2.4 Bayes theorem – the categorical version 22 2.5 Bayes theorem – the continuous version 23 2.6 The binomial case 24 2.7 The Gaussian case 30 2.8 The Poisson case 36 2.9 The prior and posterior distribution of h(θ) 40 2.10 Bayesian versus likelihood approach 40 2.11 Bayesian versus frequentist approach 41 2.12 The different modes of the Bayesian approach 41 2.13 An historical note on the Bayesian approach 42 2.14 Closing remarks 44 Exercises 44 3 Introduction to Bayesian inference 46 3.1 Introduction 46 3.2 Summarizing the posterior by probabilities 46 3.3 Posterior summary measures 47 3.3.1 Characterizing the location and variability of the posterior distribution 47 3.3.2 Posterior interval estimation 49 3.4 Predictive distributions 51 3.4.1 The frequentist approach to prediction 52 3.4.2 The Bayesian approach to prediction 53 3.4.3 Applications 54 3.5 Exchangeability 58 3.6 A normal approximation to the posterior 60 3.6.1 A Bayesian analysis based on a normal approximation to the likelihood 60 3.6.2 Asymptotic properties of the posterior distribution 62 3.7 Numerical techniques to determine the posterior 63 3.7.1 Numerical integration 63 3.7.2 Sampling from the posterior 65 3.7.3 Choice of posterior summary measures 72 3.8 Bayesian hypothesis testing 72 3.8.1 Inference based on credible intervals 72 3.8.2 The Bayes factor 74 3.8.3 Bayesian versus frequentist hypothesis testing 76 3.9 Closing remarks 78 Exercises 79 4 More than one parameter 82 4.1 Introduction 82 4.2 Joint versus marginal posterior inference 83 4.3 The normal distribution with μ and σ2 unknown 83 4.3.1 No prior knowledge on μ and σ2 is available 84 4.3.2 An historical study is available 86 4.3.3 Expert knowledge is available 88 4.4 Multivariate distributions 89 4.4.1 The multivariate normal and related distributions 89 4.4.2 The multinomial distribution 90 4.5 Frequentist properties of Bayesian inference 92 4.6 Sampling from the posterior distribution: The Method of Composition 93 4.7 Bayesian linear regression models 96 4.7.1 The frequentist approach to linear regression 96 4.7.2 A noninformative Bayesian linear regression model 97 4.7.3 Posterior summary measures for the linear regression model 98 4.7.4 Sampling from the posterior distribution 99 4.7.5 An informative Bayesian linear regression model 101 4.8 Bayesian generalized linear models 101 4.9 More complex regression models 102 4.10 Closing remarks 102 Exercises 102 5 Choosing the prior distribution 104 5.1 Introduction 104 5.2 The sequential use of Bayes theorem 104 5.3 Conjugate prior distributions 106 5.3.1 Univariate data distributions 106 5.3.2 Normal distribution – mean and variance unknown 109 5.3.3 Multivariate data distributions 110 5.3.4 Conditional conjugate and semiconjugate distributions 111 5.3.5 Hyperpriors 112 5.4 Noninformative prior distributions 113 5.4.1 Introduction 113 5.4.2 Expressing ignorance 114 5.4.3 General principles to choose noninformative priors 115 5.4.4 Improper prior distributions 119 5.4.5 Weak/vague priors 120 5.5 Informative prior distributions 121 5.5.1 Introduction 121 5.5.2 Data-based prior distributions 121 5.5.3 Elicitation of prior knowledge 122 5.5.4 Archetypal prior distributions 126 5.6 Prior distributions for regression models 129 5.6.1 Normal linear regression 129 5.6.2 Generalized linear models 131 5.6.3 Specification of priors in Bayesian software 134 5.7 Modeling priors 134 5.8 Other regression models 136 5.9 Closing remarks 136 Exercises 137 6 Markov chain Monte Carlo sampling 139 6.1 Introduction 139 6.2 The Gibbs sampler 140 6.2.1 The bivariate Gibbs sampler 140 6.2.2 The general Gibbs sampler 146 6.2.3 Remarks∗ 150 6.2.4 Review of Gibbs sampling approaches 152 6.2.5 The Slice sampler∗ 153 6.3 The Metropolis(–Hastings) algorithm 154 6.3.1 The Metropolis algorithm 155 6.3.2 The Metropolis–Hastings algorithm 157 6.3.3 Remarks∗ 159 6.3.4 Review of Metropolis(–Hastings) approaches 161 6.4 Justification of the MCMC approaches∗ 162 6.4.1 Properties of the MH algorithm 164 6.4.2 Properties of the Gibbs sampler 165 6.5 Choice of the sampler 165 6.6 The Reversible Jump MCMC algorithm∗ 168 6.7 Closing remarks 172 Exercises 173 7 Assessing and improving convergence of the Markov chain 175 7.1 Introduction 175 7.2 Assessing convergence of a Markov chain 176 7.2.1 Definition of convergence for a Markov chain 176 7.2.2 Checking convergence of the Markov chain 176 7.2.3 Graphical approaches to assess convergence 177 7.2.4 Formal diagnostic tests 180 7.2.5 Computing the Monte Carlo standard error 186 7.2.6 Practical experience with the formal diagnostic procedures 188 7.3 Accelerating convergence 189 7.3.1 Introduction 189 7.3.2 Acceleration techniques 189 7.4 Practical guidelines for assessing and accelerating convergence 194 7.5 Data augmentation 195 7.6 Closing remarks 200 Exercises 201 8 Software 202 8.1 WinBUGS and related software 202 8.1.1 A first analysis 203 8.1.2 Information on samplers 206 8.1.3 Assessing and accelerating convergence 207 8.1.4 Vector and matrix manipulations 208 8.1.5 Working in batch mode 210 8.1.6 Troubleshooting 212 8.1.7 Directed acyclic graphs 212 8.1.8 Add-on modules: GeoBUGS and PKBUGS 214 8.1.9 Related software 214 8.2 Bayesian analysis using SAS 215 8.2.1 Analysis using procedure GENMOD 215 8.2.2 Analysis using procedure MCMC 217 8.2.3 Other Bayesian programs 220 8.3 Additional Bayesian software and comparisons 221 8.3.1 Additional Bayesian software 221 8.3.2 Comparison of Bayesian software 222 8.4 Closing remarks 222 Exercises 223 Part II Bayesian Tools for Statistical Modeling 9 Hierarchical models 227 9.1 Introduction 227 9.2 The Poisson-gamma hierarchical model 228 9.2.1 Introduction 228 9.2.2 Model specification 229 9.2.3 Posterior distributions 231 9.2.4 Estimating the parameters 232 9.2.5 Posterior predictive distributions 237 9.3 Full versus empirical Bayesian approach 238 9.4 Gaussian hierarchical models 240 9.4.1 Introduction 240 9.4.2 The Gaussian hierarchical model 240 9.4.3 Estimating the parameters 241 9.4.4 Posterior predictive distributions 243 9.4.5 Comparison of FB and EB approach 244 9.5 Mixed models 244 9.5.1 Introduction 244 9.5.2 The linear mixed model 244 9.5.3 The generalized linear mixed model 248 9.5.4 Nonlinear mixed models 253 9.5.5 Some further extensions 256 9.5.6 Estimation of the random effects and posterior predictive distributions 256 9.5.7 Choice of the level-2 variance prior 258 9.6 Propriety of the posterior 260 9.7 Assessing and accelerating convergence 261 9.8 Comparison of Bayesian and frequentist hierarchical models 263 9.8.1 Estimating the level-2 variance 263 9.8.2 ML and REml estimates compared with Bayesian estimates 264 9.9 Closing remarks 265 Exercises 265 10 Model building and assessment 267 10.1 Introduction 267 10.2 Measures for model selection 268 10.2.1 The Bayes factor 268 10.2.2 Information theoretic measures for model selection 274 10.2.3 Model selection based on predictive loss functions 286 10.3 Model checking 288 10.3.1 Introduction 288 10.3.2 Model-checking procedures 289 10.3.3 Sensitivity analysis 295 10.3.4 Posterior predictive checks 300 10.3.5 Model expansion 308 10.4 Closing remarks 316 Exercises 316 11 Variable selection 319 11.1 Introduction 319 11.2 Classical variable selection 320 11.2.1 Variable selection techniques 320 11.2.2 Frequentist regularization 322 11.3 Bayesian variable selection: Concepts and questions 325 11.4 Introduction to Bayesian variable selection 326 11.4.1 Variable selection for K small 326 11.4.2 Variable selection for K large 330 11.5 Variable selection based on Zellner’s g-prior 333 11.6 Variable selection based on Reversible Jump Markov chain Monte Carlo 336 11.7 Spike and slab priors 339 11.7.1 Stochastic Search Variable Selection 340 11.7.2 Gibbs Variable Selection 343 11.7.3 Dependent variable selection using SSVS 345 11.8 Bayesian regularization 345 11.8.1 Bayesian LASSO regression 346 11.8.2 Elastic Net and further extensions of the Bayesian LASSO 350 11.9 The many regressors case 351 11.10 Bayesian model selection 355 11.11 Bayesian model averaging 357 11.12 Closing remarks 359 Exercises 360 Part III Bayesian Methods in Practical Applications 12 Bioassay 365 12.1 Bioassay essentials 365 12.1.1 Cell assays 365 12.1.2 Animal assays 366 12.2 A generic in vitro example 369 12.3 Ames/Salmonella mutagenic assay 371 12.4 Mouse lymphoma assay (L5178Y TK+/−) 373 12.5 Closing remarks 374 13 Measurement error 375 13.1 Continuous measurement error 375 13.1.1 Measurement error in a variable 375 13.1.2 Two types of measurement error on the predictor in linear and nonlinear models 376 13.1.3 Accommodation of predictor measurement error 378 13.1.4 Nonadditive errors and other extensions 382 13.2 Discrete measurement error 382 13.2.1 Sources of misclassification 382 13.2.2 Misclassification in the binary predictor 383 13.2.3 Misclassification in a binary response 386 13.3 Closing remarks 389 14 Survival analysis 390 14.1 Basic terminology 390 14.1.1 Endpoint distributions 391 14.1.2 Censoring 392 14.1.3 Random effect specification 393 14.1.4 A general hazard model 393 14.1.5 Proportional hazards 394 14.1.6 The Cox model with random effects 394 14.2 The Bayesian model formulation 394 14.2.1 A Weibull survival model 395 14.2.2 A Bayesian AFT model 397 14.3 Examples 397 14.3.1 The gastric cancer study 397 14.3.2 Prostate cancer in Louisiana: A spatial AFT model 401 14.4 Closing remarks 406 15 Longitudinal analysis 407 15.1 Fixed time periods 407 15.1.1 Introduction 407 15.1.2 A classical growth-curve example 408 15.1.3 Alternate data models 414 15.2 Random event times 417 15.3 Dealing with missing data 420 15.3.1 Introduction 420 15.3.2 Response missingness 421 15.3.3 Missingness mechanisms 422 15.3.4 Bayesian considerations 424 15.3.5 Predictor missingness 424 15.4 Joint modeling of longitudinal and survival responses 424 15.4.1 Introduction 424 15.4.2 An example 425 15.5 Closing remarks 429 16 Spatial applications: Disease mapping and image analysis 430 16.1 Introduction 430 16.2 Disease mapping 430 16.2.1 Some general spatial epidemiological issues 431 16.2.2 Some spatial statistical issues 433 16.2.3 Count data models 433 16.2.4 A special application area: Disease mapping/risk estimation 434 16.2.5 A special application area: Disease clustering 438 16.2.6 A special application area: Ecological analysis 443 16.3 Image analysis 444 16.3.1 fMRI modeling 446 16.3.2 A note on software 455 17 Final chapter 456 17.1 What this book covered 456 17.2 Additional Bayesian developments 456 17.2.1 Medical decision making 456 17.2.2 Clinical trials 457 17.2.3 Bayesian networks 457 17.2.4 Bioinformatics 458 17.2.5 Missing data 458 17.2.6 Mixture models 458 17.2.7 Nonparametric Bayesian methods 459 17.3 Alternative reading 459 Appendix: Distributions 460 A.1 Introduction 460 A.2 Continuous univariate distributions 461 A.3 Discrete univariate distributions 477 A.4 Multivariate distributions 481 References 484 Index 509

Read more less

Book Synopsis"The Tutorials in Biostatistics" are a feature of the journal, "Statistics in Medicine" (SIM).Trade Review"The articles within the volume are self-contained, well written, and accessible to readers of widely ranging backgrounds. These volumes should be extremely valuable to practitioners…" (Journal of the American Statistical Association, December 2005) "The biostatistical practitioners who use a broad range of statistical methods would definitely find beneficial and useful to have 'Tutorials in Biostatistics'…" (E-STREAMS, September 2005) “ …this book gives a well-written and concise overview of selected biostatistical subjects.” (Journal of the Royal Statistical Society, Series A, June 2005)Table of ContentsPreface. Preface to Volume 1. Part I: OBSERVATIONAL STUDIES/EPIDEMIOLOGY. 1.1 Epidemiology. Computing Estimates of Incidence, including Lifetime Risk: Alzheimer’s Disease in the Framingham Study. The Practical Incidence Estimators (PIE) Macro. (Alexa Beiser et al). The Applications of Capture-Recapture Models to Epidemiological Data. (Anne Chao et al). 1.2 Adjustment Methods. Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non-Randomized Control Group (Ralph B. D’Agostino Jr.). 1.3 Agreement Statistics. Kappa Coefficients in Medical Research (Helen Chmura Kraemer et al). 1.4 Survival Models. Survival Analysis in Observational Studies (Kate Bull and David J. Spiegelhalter). Methods for Interval-Censored Data (Jane C. Lindsey and Louise M. Ryan). Analysis of Binary Outcomes in Longitudinal Studies Using Weighted Estimating Equations and Discrete-Time Survival Methods: Prevalence and Incidence of Smoking in an Adolescent Cohort (John B. Carlin et al). Part II: PROGNOSTIC/CLINICAL PREDICTION MODELS. 2.1 Prognostic Variables. Categorizing a Prognostic Variable: Review of Methods, Code for Easy Implementation and Applications to Decision-Making about Cancer Treatments (Madhu Mazumdar and Jill R. Glassman). 2.2 Prognostic/Clinical Prediction Models. Development of Health Risk Appraisal Functions in the Presence of Multiple Indicators: The Framingham Study Nursing Home Institutionalization Model (R. B. D’Agostino et al). Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors (Frank E. Harrell Jr et al). Development of a Clinical Prediction Model for an Ordinal Outcome: The World Health Organization Multicentre Study of Clinical Signs and Etiological Agents of Pneumonia, Sepsis and Meningitis in Young Infants (Frank E. Harrell Jr. et al). Using Observational Data to Estimate Prognosis: An Example Using a Coronary Artery Disease Registry (Elizabeth R. DeLong et al). Part III: CLINICAL TRIALS. 3.1 Design. Designing Studies for Dose Response (Weng Kee Wong and Peter A. Lachenbruch.). 3.2 Monitoring. Bayesian Data Monitoring in Clinical Trials (Peter M. Fayers et al). 3.3 Analysis. Longitudinal Data Analysis (Repeated Measures) in Clinical Trials (Paul S. Albert). Repeated Measures in Clinical Trials: Simple Strategies for Analysis Using Summary Measures (Stephen Senn et al). Strategies for Comparing Treatments on a Binary Response with Multi-Centre Data (Alan Agresti, and Jonathan Hartzel). A Review of Tests for Detecting a Monotone Dose–Response Relationship with Ordinal Response Data (Christy Chuang-Stein and Alan Agresti).

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisEmerging Infectious Diseases Emerging Infectious Diseases offers an introduction to emerging and reemerging infectious disease, focusing on significant illnesses found in various regions of the world. Many of these diseases strike tropical regions or developing countries with particular virulence, others are found in temperate or developed areas, and still other microbes and infections are more indiscriminate. This volume includes information on the underlying mechanisms of microbial emergence, the technology used to detect them, and the strategies available to contain them. The author describes the diseases and their causative agents that are major factors in the health of populations the world over. The book contains up-to-date selections from infectious disease journals as well as information from the Centers for Disease Control and Prevention, the World Health Organization, MedLine Plus, and the American Society for Microbiology. Perfect for studenTable of ContentsTables and Figures vii Preface xv The Author xvii Acknowledgments xviii Part 1: Introduction to Emerging Infectious Diseases Chapter 1: Infectious Diseases Past and Present 3 Major Concepts 4 • History of Infectious Diseases 5 • The Role of Infectious Diseases in the World Today 8 • The Links Between Infectious Diseases, Poverty, and Civil Unrest 10 • Emerging and Reemerging Infectious Diseases 12 • Factors Contributing to the Emergence of New Infectious Diseases and the Spread and Evolution of Older Diseases 15 • Timeline 18 Chapter 2: Of Microbes and Men 27 Major Concepts 28 • Introduction 30 • Infectious Agents: The Enemy Combatants 30 • Genetic Information and the Making of Proteins: Preparing the Armament 36 • The Immune Response: Humans Fight Back, Part One 40 • Antimicrobial Agents: Humans Fight Back, Part Two 46 Part 2: Bacterial Infections Chapter 3: Lyme Disease 55 Major Concepts 56 • Introduction 58 • History 60 • The Disease 61 • The Causative Agent 63 • The Immune Response 66 • Diagnosis 67 • Treatment 68 • Prevention 69 • Surveillance 71 Chapter 4: Human Ehrlichiosis 75 Major Concepts 76 • Introduction 77 • History 78 • The Diseases 79 • The Causative Agents 88 • The Immune Response 89 • Diagnosis 90 • Treatment 91 • Prevention 92 • Surveillance 92 Chapter 5: Bartonella Infections 97 Major Concepts 98 • Introduction 99 • History 99 • The Diseases 101 • The Causative Agents 106 • The Immune Response 109 • Diagnosis 110 • Treatment 111 • Prevention 111 • Surveillance 112 Chapter 6: Group A Streptococci 117 Major Concepts 118 • Introduction 119 • History 120 • The Diseases 121 • The Causative Agents 127 • The Immune Response 131 • Diagnosis 132 • Treatment 133 • Prevention 134 • Surveillance 135 Chapter 7: Escherichia coli O157:H7 139 Major Concepts 140 • Introduction 141 • History 142 • The Diseases 143 • The Causative Agents 145 • The Immune Response 151 • Diagnosis 152 • Treatment 153 • Prevention 153 • Surveillance 155 Chapter 8: Helicobacter pylori, Ulcers, and Cancer 161 Major Concepts 162 • Introduction 163 • History 164 • The Diseases 165 • The Causative Agent 168 • The Immune Response 171 • Diagnosis 172 • Treatment 173 • Prevention 174 • Surveillance 175 Chapter 9: Legionnaires’ Disease and Pontiac Fever 181 Major Concepts 182 • Introduction 183 • History 184 • The Diseases 185 • The Causative Agent 186 • The Immune Response 191 • Diagnosis 194 • Treatment 197 • Prevention 197 • Surveillance 199 Chapter 10: Pulmonary Tuberculosis and Multidrug Resistance 205 Major Concepts 206 • Introduction 207 • History 208 • The Disease 209 • The Causative Agents 212 • The Immune Response 213 • Detection and Diagnosis 214 • Treatment and Drug Resistance 216 • Prevention 219 • Surveillance 220 Chapter 11: Emerging Bacterial Drug Resistance 225 Major Concepts 226 • Introduction 227 • History 228 • The Diseases, Causative Agents, and Treatment Options 229 • Mechanisms of Resistance 235 • Diagnosis 239 • Prevention 240 • Surveillance 240 Part 3: Viral Infections Chapter 12: Marburg and Ebola Hemorrhagic Fevers 247 Major Concepts 248 • Introduction 249 • History 250 • The Diseases 254 • The Causative Agents 257 • The Immune Response 262 • Diagnosis 263 • Treatment 264 • Prevention 264 • Surveillance 267 Chapter 13: American Hemorrhagic Fevers 273 Major Concepts 274 • Introduction 275 • History 277 • The Diseases 278 • The Causative Agents 282 • The Immune Response 285 • Diagnosis 286 • Treatment 287 • Prevention 287 • Surveillance 288 Chapter 14: Lassa Hemorrhagic Fever 293 Major Concepts 294 • Introduction 295 • History 296 • The Disease 298 • The Causative Agent 300 • The Immune Response 303 • Diagnosis 304 • Treatment 304 • Prevention 306 • Surveillance 308 Chapter 15: Dengue Fever and Dengue Hemorrhagic Fever 313 Major Concepts 314 • Introduction 315 • History 316 • The Diseases 318 • The Causative Agent 321 • The Immune Response 324 • Diagnosis 327 • Treatment 327 • Prevention 328 • Surveillance 329 Chapter 16: The Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome 335 Major Concepts 336 • Introduction 338 • History 339 • The Diseases 341 • The Causative Agent 344 • The Immune Response 350 • Diagnosis and Detection 355 • Treatment 355 • Prevention 357 • Surveillance 358 Chapter 17: Human Herpesvirus 8 and Kaposi’s Sarcoma 365 Major Concepts 366 • Introduction 367 • History 368 • The Diseases 368 • The Causative Agent 373 • The Immune Response 378 • Diagnosis 379 • Treatment 380 • Prevention 383 • Surveillance 383 Chapter 18: Hepatitis C 389 Major Concepts 390 • Introduction 391 • History 392 • The Diseases 392 • The Causative Agent 397 • The Immune Response 399 • Diagnosis 401 • Treatment 402 • Prevention 403 • Surveillance 404 Chapter 19: Epidemic and Pandemic Influenza 409 Major Concepts 410 • Introduction 411 • History 412 • The Disease 414 • The Causative Agent 415 • The Immune Response 421 • Diagnosis 421 • Treatment 422 • Prevention 422 • Surveillance 425 Chapter 20: Hantavirus Pulmonary Syndrome 431 Major Concepts 432 • Introduction 433 • History 435 • The Diseases 435 • The Causative Agents 439 • The Immune Response 444 • Diagnosis 445 • Treatment 446 • Prevention 447 • Surveillance 450 Chapter 21: Severe Acute Respiratory Syndrome 455 Major Concepts 456 • Introduction 457 • History 457 • The Disease 460 • The Causative Agent 461 • The Immune Response 464 • Diagnosis 465 • Treatment 466 • Prevention 467 • Surveillance 469 Chapter 22: West Nile Disease in the United States 475 Major Concepts 476 • Introduction 477 • History 477 • The Diseases 481 • The Causative Agent 484 • The Immune Response 487 • Diagnosis 488 • Treatment 489 • Prevention 490 • Surveillance 493 Chapter 23: Monkeypox 499 Major Concepts 500 • Introduction 501 • History 502 • The Disease 505 • The Causative Agent 508 • The Immune Response 511 • Diagnosis 513 • Treatment 514 • Prevention 514 • Surveillance 516 Part 4: Parasitic Infections Chapter 24: Malaria: Reemergence and Recent Successes 523 Major Concepts 524 • Introduction 526 • History 526 • The Disease 528 • The Causative Agents 529 • The Immune Response 533 • Diagnosis 535 • Treatment and Drug Resistance 535 • Prevention: Failures and Successes 537 • Surveillance 541 Chapter 25: Babesiosis 547 Major Concepts 548 • Introduction 549 • History 549 • The Disease 550• The Causative Agent 553 • The Immune Response 557 • Diagnosis 558 • Treatment 558 • Prevention 560 • Surveillance 560 Chapter 26: Cryptosporidiosis 565 Major Concepts 566 • Introduction 567 • History 568 • The Disease 569 • The Causative Agents 570 • The Immune Response 576 • Diagnosis 577 • Treatment 578 • Prevention 580 • Surveillance 581 Chapter 27: Chagas’ Disease and Its Emergence in the United States 585 Major Concepts 586 • Introduction 587 • History 587 • The Disease 588 • The Causative Agent 591 • The Immune Response 595 • Diagnosis 598 • Treatment 599 • Prevention 600 • Surveillance 601 Part 5: Infectious Proteins Chapter 28: Creutzfeldt-Jakob Disease and Other Transmissible Spongiform Encephalopathies 609 Major Concepts 610 • Introduction 611 • History 612 • The Diseases 613 • The Causative Agents 621 • The Immune Response 625 • Diagnosis 626 • Treatment 627 • Prevention 628 • Surveillance 628 Part 6: Special Issues in Infectious Diseases Chapter 29: The Emerging Importance of Infectious Diseases in the Immunosuppressed 635 Major Concepts 636 • Introduction 637 • Immunosuppressed Populations 637 • Selected Causes of Immunosuppression 638 • Infectious Diseases of the Immunosuppressed 642 Chapter 30: The Emerging Threat of Bioweapons 667 Major Concepts 668 • Introduction 669 • History 670 • Bioterrorism Agents and Diseases 671 • The Threat of Agroterrorism 692 • Preparation for Biological Attacks 693 • Protective Vaccines 694 Glossary 701 Index 723

Read more less

Book SynopsisThis book offers an important reference source about the most common classes of pesticides for researchers engaged in the area of neurotoxicology, metabolism, and epidemiology. The book presents details about thorough characterization of target and non-target enzymes and proteins involved in toxicity and metabolism; and epidemiology of poisonings and fatalities in people from short- and long- term exposures to these pesticides in different occupational settings on an individual country basis as well as on a global basis. The early portion of the book deals with metabolism, mechanisms and biomonitoring of anticholinesterase pesticides, while the later part deals with epidemiological studies, regulatory issues, and therapeutic intervention.Table of ContentsForeword (Donald J. Ecobichon). Section I. 1. Introduction (Tetsuo Satoh, Ramesh C. Gupta). Section II: Metabolism and Mechanisms. 2. ACETYLCHOLINESTERASE AND ACETYLCHOLINE RECEPTORS: BRAIN REGIONAL HETEROGENEITY (Haruo Kobayashi, Tadahiko Suzuki, Fumiaki Akahori and Tetsuo Satoh). 3. GENOMIC IMPLICATIONS OF ANTICHOLINESTERASE SENSITIVITIES (Jonathan E. Cohen, Gabrial Zimmermann, Alon Friedman and Hermona Soreq). 4. BUTYRYLCHOLINESTERASE: OVERVIEW, STRUCTURE AND FUNCTION (Oksana Lockridge, Ellen G. Duysen and Patrick Masson). 5.CARBOXYLESTERASES:OVERVIEW, STRUCTURE, FUNCTION AND POLYMORPHISM (Masakiyo Hosokawa and Tetsuo Satoh). 6. CARBOXYLESTERASES IN THE METABOLISM AND TOXICITY OF PESTICIDES (Colin J. Jackson, Juan Sanchez-Hernandez, Craig E. Wheelock and John G. Oakeshott). 7. THE METABOLIC ACTIVATION AND DETOXICATION OF ANTICHOLINESTERASE INSECTICIDES (Janice E. Chambers, Edward C. Meek and Matthew Ross). 8. PARAOXONASE 1: STRUCTURE, FUNCTION AND POLYMORPHISMS (Lucio G. Costa, Clement E. Furlong). 9. LONG-TERM NEUROTOXICOLOGICAL EFFECTS OF ANTICHOLINESTERASES AFTER EITHER ACUTE AND CHRONIC EXPOSURE (Angelo Moretto, Manuela Tiramani and Claudio Colosio). 10. MOLECULAR TOXICOLOGY OF NEUROPATHY TARGET ESTERASE (Yi-Jun Wu and Ping-An Chang). 11. DETOXICATION OF ANTICHOLINESTERASE PESTICIDES (Miguel A. Sogorb and Eugennio Vilanova). Section III: Toxicity and Biomonitoring. 12. INVOLVEMENT OF OXIDATIVE STRESS IN ANTICHOLINESTERASE PESTICIDES TOXICITY (Dejan Milatovic, Ramesh C. Gupta, Snjezana Zaja-Milanovic, Gregory Barners and Michael Aschner). 13.CENTRAL MECHANISMS OF SEIZURES AND LETHALITY FOLLOWING ANTICHOLINESTERASE PESTICIDE EXPOSURE (Andrzej Dekundy and Rafal M. Kaminski). 14. APOPTOSIS INDUCED BY ANTICHOLINESTERASE PESTICIDES (Qing Li). 15. GENE EXPRESSION (Shirin Pournourmahammadi and Mohammad Abdollahi). 16. ORGANOPHOSPHATES AS ENDOCRINE DISRUPTORS (Shigeyuki Kitamura, Kazumi Sugihara, Nariaki Fujimoto and Takeshi Yamazaki). 17. DEVELOPMENTAL NEUROTOXICITY OF ANTICHOLINESTERASE PESTICIDES (John Flaskos and Magdalini Sachana). 18.TOXICITY OF ANTICHOLINESTERASE PESTICIDES IN NEONATES AND CHILDREN (Diane Rohlman and Linda McCauley). 19. NEUROTOXICITY OF ORGANOPHOSPHATES AND CARBAMATES (Kiran Dip Gill, Govinder Flora and Swaran J.S. Flora). 20. BIOMONITORING OF PESTICIDES: PHARMACOKINETICS OF ORGANOPHOSPHORUS AND CARBAMATE INSECTICIDES (Charles Timchalk). 21. NOVEL BIOMARKERS OF ORGANOPHOSPHATE EXPOSURE (Tetsuo Satoh, Salmaan H. Inayat-Hussain, Michihiro Kamishima and Jun Ueyama). 22. BIOMARKERS OF CARCINOGENESIS IN RELATION TO PESTICIDES POISONING (Manashi Bagchi, Shirley Zafra-Stone, Francis C. Lau and Debasis Bagchi). 23. ANTICHOLINESTERASE PESTICIDES INTERACTION (Ramesh C. Gupta and Dejan Milatovic). 24. INTERACTION OF ANTICHOLINESTERASE PESTICIDES WITH METALS (Jitendra K. Malik, Avinash G. Telang, Ashok Kumar and Ramesh C. Gupta). Section IV: Epidemiological studies. 25. GLOBAL IMPACT (Claudio Colosio, Francesca Vellere and Angelo Moretto). 26. CHILE (Floria Pancetti, Muriel Ramirez and Mauricio Castillo). 27. CHINA (Yueming Jiang). 28. EGYPT (Sameeh A. Mansour). 29. GREECE (Maria Stefanidou, S. Athanaselis, C. Spiliopoulou and C. Maravelias). 30. INDIA (Pawan K. Gupta). 31. IRAN (Mohammad Abdollahi). 32. ISRAEL (Yoram Finkelstein). 33. JAPAN (Takemi Yoshida and Yumiko Kuroki). 34. KOREA (Hyung-Keun RoBum Jin Oh, Mi-Jin Lee and Joo-Hyun Suh). 35. MEXICO (Betzabet Quintanilla-Vega, Norma Pérez-Herrera and Elizabeth Rojas-Garcia). 36. SERBIA (Milan Jokanović, Biljana Antonijević and Slavica Vučinić). 37. SPAIN (Antonio F. Hernández, Tesifón Parrón, José L. Serrano and Porfirio Marín, on behalf of the ESPAPP group). 38. TAIWAN (Tzeng Jih Lin,Dong-Zeng Hung, Jin-Lian Tsai, Sheng-Chuan Hu and Jou-Fang Deng). 39. THAILAND (Winai Wananukul). 40. TURKEY (Ismet COK). 41. U.S.A. (Anna M. Fan). Section V. 42. Regulatory Aspects (Kai Savolainen). Section VI. 43. Medical Treatment of Poisoning with Organophosphates and Carbamates (Milan Jokanović).

Read more less

Book SynopsisThe only book available in the area of forward-time population genetics simulationsapplicable to both biomedical and evolutionary studies The rapid increase of the power of personal computers has led to the use of serious forward-time simulation programs in genetic studies. Forward-Time Population Genetics Simulations presents both new and commonly used methods, and introduces simuPOP, a powerful and flexible new program that can be used to simulate arbitrary evolutionary processes with unique features like customized chromosome types, arbitrary nonrandom mating schemes, virtual subpopulations, information fields, and Python operators. The book begins with an overview of important concepts and models, then goes on to show how simuPOP can simulate a number of standard population genetics modelswith the goal of demonstrating the impact of genetic factors such as mutation, selection, and recombination on standard Wright-Fisher models. The rest of the book is devoted to aTable of ContentsPreface ix Acknowledgments xiii List of examples xxiii 1. Basic concepts and models 1 1.1 Biological and genetic concepts 2 1.2 Population and evolutionary genetics 6 1.3 Statistical genetics and genetic epidemiology 17 2. Simulation of population genetics models 25 2.1 Random genetic drift 25 2.2 Demographic models 29 2.3 Mutation 31 2.4 Migration 34 2.5 Recombination and linkage disequilibrium 36 2.6 Natural selection 37 2.7 Genealogy of forward-time simulations 41 3. Ascertainment bias in population genetics 47 3.1 Introduction 47 3.2 Methods 49 3.3 Results 54 3.4 Discussion and Conclusions 58 4. Observing properties of evolving populations 63 4.1 Introduction 64 4.2 Simulation of the evolution of allele spectra 66 4.3 Extensions to the basic model 78 5. Simulating populations with complex human diseases 89 5.1 Introduction 89 5.2 Controlling disease allele frequencies at the present generation 91 5.3 Forward-time simulation of realistic samples 102 5.4 Discussion 119 6. Nonrandom mating and its applications 125 6.1 Assortative mating 126 6.2 More complex non-random mating schemes 132 6.3 Hetergeneous mating schemes 140 6.4 Simulation of age structured populations 145 Appendix: Forward-time simulations using stimulPOP 157 A.1 Introduction 157 A.2 Population 160 A.3 Operators 172 A.4 Evolve on or more populations 181 A.5 A complete stimuPOP script 185

Read more less

Book SynopsisProvides timely applications, modifications, and extensions of experimental designs for a variety of disciplines Design and Analysis of Experiments, Volume 3: Special Designs and Applications continues building upon the philosophical foundations of experimental design by providing important, modern applications of experimental design to the many fields that utilize them. The book also presents optimal and efficient designs for practice and covers key topics in current statistical research. Featuring contributions from leading researchers and academics, the book demonstrates how the presented concepts are used across various fields from genetics and medicinal and pharmaceutical research to manufacturing, engineering, and national security. Each chapter includes an introduction followed by the historical background as well as in-depth procedures that aid in the construction and analysis of the discussed designs. Topical coverage includes: Trade Review “The presentation by Wiley is superb, as we have come to expect. All in all, this is a first class offering.”( International Statistical Review, 1 October 2012) Table of ContentsPreface xvii Contributors xxi 1 Genetic Crosses Experiments 1 Murari Singh, Sudhir Gupta, and Rajender Parsad 1.1 Introduction, 1 1.2 Basic Objectives and Models, 2 1.3 Diallel Mating Design of Type I, 8 1.4 Diallel Crosses: Type II Designs, 14 1.5 Partial Diallel Crosses: No Blocking or Complete Blocks, 25 1.6 Partial Diallel Crosses in Incomplete Blocks, 32 1.7 Optimality, 44 1.8 Robustness, 59 1.9 Three- or Higher-Way Crosses, 61 1.10 Computation, 65 2 Design of Gene Expression Microarray Experiments 73 Dan Nettleton 2.1 Introduction, 73 2.2 Gene Expression Microarray Technology, 74 2.3 Preprocessing of Microarray Fluorescence Intensities, 76 2.4 Introduction to Gene Expression Microarray Experimental Design, 80 2.5 Two-Treatment Experiments Using Two-Color Microarrays, 81 2.6 Two-Color Microarray Experiments Involving More Than Two Treatments, 86 2.7 Multifactor Two-Color Microarray Experiments, 89 2.8 Phase 2 Designs for Complex Phase 1 Designs, 94 3 Spatial Analysis of Agricultural Field Experiments 109 Joanne K. Stringer, Alison B. Smith, and Brian R. Cullis 3.1 Introduction, 109 3.2 Methods to Account for Spatial Variation, 110 3.3 A Spatial Linear Mixed Model, 116 3.4 Analysis of Examples, 122 4 Optimal Designs for Generalized Linear Models 137 John Stufken and Min Yang 4.1 Introduction, 137 4.2 Notation and Basic Concepts, 141 4.3 Tools for Finding Locally Optimal Designs, 145 4.4 GLMs with Two Parameters, 149 4.5 GLMs with Multiple Parameters, 155 4.6 Summary and Concluding Comments, 161 5 Design and Analysis of Randomized Clinical Trials 165 Janet Wittes and Zi-Fan Yu 5.1 Overview, 165 5.2 Components of a Randomized Clinical Trial, 168 5.3 Bias, 175 5.4 Statistical Analysis of Randomized Clinical Trials, 182 5.5 Failure Time Studies, 184 5.6 Other Topics, 206 6 Monitoring Randomized Clinical Trials 213 Eric S. Leifer and Nancy L. Geller 6.1 Introduction, 213 6.2 Normally Distributed Outcomes, 215 6.3 Brownian Motion Properties, 217 6.4 Brief Historical Overview of Group Sequential Methods, 219 6.5 Dichotomous Outcomes, 223 6.6 Time-to-Event Outcomes, 225 6.7 Unconditional Power, 227 6.8 Conditional Power, 229 6.9 Spending Functions, 232 6.10 Flexibility and Properties of Spending Functions, 233 6.11 Modifying the Trial’s Sample Size Based on a Nuisance Parameter, 235 6.12 Sample Size Modification Based on the Interim Treatment Effect, 240 6.13 Concluding Remarks, 246 7 Adaptive Randomization in Clinical Trials 251 Lanju Zhang and William F. Rosenberger 7.1 Introduction, 251 7.2 Adaptive Randomization Procedures, 252 7.3 Likelihood-Based Inference, 264 7.4 Randomization-Based Inference, 269 7.5 Conclusions and Practical Considerations, 276 8 Search Linear Model for Identification and Discrimination 283 Subir Ghosh 8.1 Introduction, 283 8.2 General Linear Model with Fixed Effects, 284 8.3 Search Linear Model, 285 8.4 Applications, 288 8.5 Effects of Noise in Performance Comparison, 293 9 Minimum Aberration and Related Criteria for Fractional Factorial Designs 299 Hegang H. Chen and Ching-Shui Cheng 9.1 Introduction, 299 9.2 Projections of Fractional Factorial Designs, 302 9.3 Estimation Capacity, 304 9.4 Clear Two-Factor Interactions, 307 9.5 Estimation Index, 310 9.6 Estimation Index, Minimum Aberration, and Maximum Estimation Capacity, 314 9.7 Complementary Design Theory for Minimum Aberration Designs, 315 9.8 Nonregular Designs and Orthogonal Arrays, 317 9.9 Generalized Minimum Aberration, 320 9.10 Optimal Fractional Factorial Block Designs, 322 10 Designs for Choice Experiments for the Multinomial Logit Model 331 Deborah J. Street and Leonie Burgess 10.1 Introduction, 331 10.2 Definitions, 332 10.3 The MNL Model, 335 10.4 Design Comparisons, 338 10.5 Optimal Designs for DCEs, 340 10.6 Using Combinatorial Designs to Construct DCEs, 364 10.7 Bayesian Work, 368 10.8 Best–Worst Experiments, 368 10.9 Miscellaneous Topics, 370 11 Computer Experiments 379 Max D. Morris 11.1 Introduction, 379 11.2 Sensitivity/Uncertainty Analysis, 382 11.3 Gaussian Stochastic Process Models, 385 11.4 Inference, 389 11.5 Experimental Designs, 398 11.6 Multivariate Output, 403 11.7 Multiple Data Sources, 406 11.8 Conclusion, 409 12 Designs for Large-Scale Simulation Experiments, with Applications to Defense and Homeland Security 413 Susan M. Sanchez, Thomas W. Lucas, Paul J. Sanchez, Christopher J. Nannini, and Hong Wan 12.1 Introduction, 413 12.2 Philosophy: Evolution of Computational Experiments, 414 12.3 Application: U.S. Army Unmanned Aerial Vehicle (UAV) Mix Study, 422 12.4 Parting Thoughts, 437 13 Robust Parameter Designs 443 Timothy J. Robinson and Christine M. Anderson-Cook 13.1 Introduction, 443 13.2 Taguchi Signal-to-Noise Ratio Approach, 445 13.3 Dual Model Response Surface Methodology, 448 13.4 Single Model Response Surface Methods Using Combined Arrays, 451 13.5 Computer Generated Combined Arrays, 461 13.6 RPD Involving Quantitative and Qualitative Factors, 465 13.7 Conclusions, 466 14 Split-Plot Response Surface Designs 471 G. Geoffrey Vining 14.1 Introduction, 471 14.2 Differences between Agricultural and Industrial Experimentation, 472 14.3 OLS–GLS Equivalent Second-Order Split-Plot Designs and Analysis, 482 14.4 Exact Tests for the Coeffi cients, 488 14.5 Proper Residuals for Checking Assumptions, 493 14.6 "Optimal" Second-Order Split-Plot Designs, 496 15 Design and Analysis of Experiments for Directional Data 501 Sango B. Otieno and Christine M. Anderson-Cook 15.1 Summary, 501 15.2 Introduction and Historical Background, 501 15.3 ANOVA for Circular Data, 509 15.4 ANOVA for Cylindrical Data, 521 15.5 ANOVA for Spherical Data, 524 15.6 Conclusions, 530 References, 531 Author Index 533 Subject Index 545

Read more less

Book Synopsis* Provides a comprehensive, in-depth treatment of statistical methods in healthcare. * Presents a reference source for practitioners and specialists in health care and drug development. * Offers a broad coverage of standards and established methods through leading edge techniques.Table of ContentsForeword xix Preface xxi Editors xxiii Contributors xxv Part One STATISTICS IN THE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS 1 Statistical Aspects in ICH, FDA and EMA Guidelines 3Allan Sampson and Ron S. Kenett 2 Statistical Methods in Clinical Trials 22Telba Irony, Caiyan Li and Phyllis Silverman 3 Pharmacometrics in Drug Development 56Serge Guzy and Robert Bauer 4 Interactive Clinical Trial Design 78Zvia Agur 5 Stage-wise Clinical Trial Experiments in Phases I, II and III 103Shelemyahu Zacks 6 Risk Management in Drug Manufacturing and Healthcare 122Ron S. Kenett 7 The Twenty-first Century Challenges in Drug Development 155Yafit Stark Part Two STATISTICS IN OUTCOMES ANALYSIS 8 The Issue of Bias in Combined Modelling and Monitoring of Health Outcomes 169Olivia A. J. Grigg 9 Disease Mapping 185Annibale Biggeri and Dolores Catelan 10 Process Indicators and Outcome Measures in the Treatment of Acute Myocardial Infarction Patients 219Alessandra Guglielmi, Francesca Ieva, Anna Maria Paganoni and Fabrizio Ruggeri 11 Meta-analysis 230Eva Negri Part Three STATISTICAL PROCESS CONTROL IN HEALTHCARE 12 The Use of Control Charts in Healthcare 253William H. Woodall, Benjamin M. Adams and James C. Benneyan 13 Common Challenges and Pitfalls Using SPC in Healthcare 268Victoria Jordan and James C. Benneyan 14 Six Sigma in Healthcare 286Shirley Y. Coleman 15 Statistical Process Control in Clinical Medicine 309Per Winkel and Nien Fan Zhang Part Four APPLICATIONS TO HEALTHCARE POLICY AND IMPLEMENTATION 16 Modeling Kidney Allocation: A Data-driven Optimization Approach 335Inbal Yahav 17 Statistical Issues in Vaccine Safety Evaluation 353Patrick Musonda 18 Statistical Methods for Healthcare Economic Evaluation 365Caterina Conigliani, Andrea Manca and Andrea Tancredi 19 Costing and Performance in Healthcare Management 386Rosanna Tarricone and Aleksandra Torbica Part Five APPLICATIONS TO HEALTHCARE MANAGEMENT 20 Statistical Issues in Healthcare Facilities Management 407Daniel P. O'Neill and Anja Drescher 21 Simulation for Improving Healthcare Service Management 426Anne Shade 22 Statistical Issues in Insurance/payor Processes 445Melissa Popkoski 23 Quality of Electronic Medical Records 456Dario Gregori and Paola Berchialla References 475 Index 481

Read more less

Book SynopsisThis new title in the World Psychiatric Association Series offers insightful commentaries from experts in PTSD. With a critical review of the evidence on causes and treatment, this concise volume will be useful to both psychiatrists and clinical psychologists as well as trainees.Trade Review“This is a valuable contribution to the psychiatric literature, helping clinicians, researchers, and policymakers focus their attention on the ongoing changes in the diagnosis, treatment, prognosis, and epidemiology of a known disorder.” (Doody’s, 13 April 2012) “The book, however, will provide a solid reference for clinicians and practitioners and is recommended.” (PsycCRITIQUES, 28 March 2012) "At the same time, there is enormous value in exploring one topic very well, and this text certainly offers trauma researchers and practitioners an authoritative synthesis and evaluation of knowledge about PTSD itself." (University of Cape Town Child Guidance Clinic, 2012)Table of ContentsPreface xi List of Contributors xv 1 PTSD and Related Disorders 1 Matthew J. Friedman Commentaries 1.1 Walking the Line in Defining PTSD: Comprehensiveness Versus Core Features 35 Chris R. Brewin 1.2 Trauma-Related Disorders in the Clinical and Legal Settings 38 Elie G. Karam 1.3 Redefining PTSD in DSM-5: Conundrums and Potentially Unintended Risks 42 Alexander C. McFarlane 2 Epidemiology of PTSD 49 Carlos Blanco Commentaries 2.1 Challenges and Future Horizons in Epidemiological Research into PTSD 75 Abdulrahman M. El-Sayed and Sandro Galea 2.2 Preventing Mental Ill-Health Following Trauma 79 Helen Herrman 2.3 PTSD Epidemiology with Particular Reference to Gender 82 Marianne Kastrup 3 Neurobiology of PTSD 89 Arieh Y. Shalev, Asaf Gilboa and Ann M. Rasmusson Commentaries 3.1 Translational Theory-Driven Hypotheses and Testing Are Enhancing Our Understanding of PTSD and its Treatment 139 Brian H. Harvey 3.2 Precipitating and design approaches to PTSD 142 Eric Vermetten 4 Pharmacotherapy of PTSD 149 Dan J. Stein and Jonathan C. Ipser Commentaries 4.1 Critical View of the Pharmacological Treatment of Trauma 163 Marcelo F. Mello 4.2 Shortcomings and Future Directions of the Pharmacotherapy of PTSD 164 Michael Van Ameringen and Beth Patterson 4.3 Dire Need for New PTSD Pharmacotherapeutics 167 Murray B. Stein 5 Psychological Interventions for Trauma Exposure and PTSD 171 Richard A. Bryant Commentaries 5.1 Psychological Interventions for PTSD in Children 203 Lucy Berliner 5.2 Challenges in the Dissemination and Implementation of Exposure-Based CBT for the Treatment of Hispanics with PTSD 205 Rafael Kichic, Mildred Vera, and Marıa L. Reyes-Rabanillo 5.3 What Else Do We Need to Know about Evidence-Based Psychological Interventions for PTSD? 208 Karina Lovell 5.4 Another Perspective on Exposure Therapy for PTSD 211 Barbara Olasov Rothbaum 6 (Disaster) Public Mental Health 217 Joop de Jong Commentaries 6.1 An Excellent Model for Low- and Middle-Income Countries 263 Dean Ajdukovic 6.2 Disaster Mental Health and Public Health: An Integrative Approach to Recovery 266 Suresh Bada Math, Channaveerachari Naveen Kumar and Maria Christine Nirmala 6.3 Transcultural Aspects of Response to Disasters 272 Tarek A. Okasha 6.4 Disaster Public Health: Health Needs, Psychological First Aid and Cultural Awareness 275 Robert J. Ursano, Matthew N. Goldenberg, Derrick Hamaoka and David M. Benedek Index 281

Read more less

Book SynopsisDuring the last twenty years statistical methodology has become of central importance in research studies in medicine and also in day-to-day clinical practice.Table of ContentsForeword. Preface. Biographical Information on the Editors. List of Contributors. Abbreviations and Acronyms. The Encyclopaedic Companion to Medical Statistics.

Read more less

Book SynopsisThe new edition of this critically praised textbook continues to provide the most comprehensive overview of the concepts, methods, and research advances in the field; particularly the application of molecular genomics and of neuroimaging. It has been revised and enhanced to capitalize on the strengths of the first and second editions while keeping it up-to-date with the field of psychiatry and epidemiology. This comprehensive publication now includes chapters on experimental epidemiology, gene-environment interactions, the use of case registries, eating disorders, suicide, childhood disorders and immigrant populations, and the epidemiology of a number of childhood disorders. As in the first and second editions, the objective is to provide a comprehensive, easy to understand overview of research methods for the non-specialist. The book is ideal for students of psychiatric epidemiology, psychiatric residents, general psychiatrists, and other mental health professionals. The boTrade Review"The Textbook of Psychiatric Epidemiology is a timely, up-to-date, and comprehensive book covering all aspects of the science of epidemiology as related to psychiatric disorders. Overall, this is a well written, wel-organized book that I highly recommend to all psychiatrists and neuroscientists who are interested in the underpinning of psychiatric epidemiology." (Journal of Clinical Psychiatry, 2013) “Overall, this book provides a thorough and understandable introduction to the field of psychiatric epidemiology, suitable for students wishing to become familiar with up-to-date applications and findings in psychiatry as they relate to public health and epidemiology.” (Doody’s, 6 April 2012) "This 3rd edition is a welcome return for this informative textbook, which will be of interest to a wide readership through its extensive scope. It covers a range of areas relevant to epidemiology and beyond with what is now the standard format involving expert authors or teams." (Acta Psychiatrica Scandinavica, 2012) "So I started this review process with a great deal of skepticism. However, during this process I have ended up reading about areas outside my own main research field with much interest, and chapters within my own areas with much pleasure and admiration for the contributions; and, I have found myself recommending individual chapters again and again to students and other people with whom I, during this period, have discussed specific projects. So, much to my own surprise, I end up warmly recommending this book to anyone who has a professional interest in the epidemiology of, and risk factors for psychiatric disorders, and a recurring need for a fast reference to a very comprehensive array of knowledge." Read the full review. (Acta Neuropsychiatrica, 2012) Table of ContentsList of Contributors. 1 Introduction to epidemiologic research methods (Glyn Lewis). 1.1 What is epidemiology? 1.2 Causation in medicine. 1.3 Causal inference. 1.4 The future for psychiatric epidemiology. 2 Analysis of categorical data: The odds ratio as a measure of association and beyond (Garrett M. Fitzmaurice and Caitlin Ravichandran). 2.1 Introduction. 2.2 Inference for a single proportion. 2.3 Analysis of 2 x 2 contingency tables. 2.4 Analysis of sets of 2 x 2 contingency tables. 2.5 Logistic regression. 2.6 Advanced topics. 2.7 Concluding remarks. 2.8 Further reading. 3 Genetic epidemiology (Stephen V. Faraone, Stephen J. Glatt and Ming T. Tsuang). 3.1 Introduction. 3.2 The chain of psychiatric genetic research. 3.3 Psychiatric genetics and psychiatric epidemiology. 4 Examining gene–environment interplay in psychiatric disorders (Judith Allardyce and Jim van Os). 4.1 Introduction. 4.2 The process of genetic epidemiology. 4.3 Gene–environment interplay takes different forms. 4.4 Gene–environment correlation. 4.5 Gene–environment interaction. 4.6 Measurement of genotype, environmental exposure and pathological phenotype. 4.7 Models of GxE. 4.8 Which scale should we use to measure GxE? 4.9 Study designs for the detection of GxE. 4.10 Threats to the validity of epidemiological GxE studies. 4.11 Epigenetic mechanisms. 5 Reliability (Patrick E. Shrout). 5.1 Introduction. 5.2 The reliability coefficient. 5.3 Designs for estimating reliability. 5.4 Statistical remedies for low reliability. 5.5 Reliability theory and binary judgements. 5.6 Reliability statistics: General. 5.7 Other reliability statistics. 5.8 Summary and conclusions. 6 Moderators and mediators: Towards the genetic and environmental bases of psychiatric disorders (Helena Chmura Kraemer). 6.1 Introduction. 6.2 Current methodological barriers. 6.3 Moderation, mediation and other ways in which risk factors 'work together'. 6.4 Extensions. 6.5 Beyond moderators and mediators. 7 Validity: Definitions and applications to psychiatric research (Jill M. Goldstein, Sara Cherkerzian and John C. Simpson). 7.1 Introduction. 7.2 Validity of a construct. 7.3 Validity of the relationships between variables. 7.4 Summary. 8 Use of register data for psychiatric epidemiology in the Nordic countries (Jouko Miettunen, Jaana Suvisaari, Jari Haukka and Matti Isohanni). 8.1 Introduction. 8.2 Registers for use in psychiatric research. 8.3 Register research in Denmark. 8.4 Register research in Finland. 8.5 Register research in Norway. 8.6 Register research in Sweden. 8.7 Discussion. 9 An introduction to mental health services research (Anna Fernandez, Alejandra Pinto-Meza, Antoni Serrano-Blanco, Jordi Alonso and Josep Maria Haro). 9.1 Introduction. 9.2 What is mental health services research? 9.3 A framework for mental health services research. 9.4 Key concepts in mental health services research. 9.5 Examples of mental health services research studies. 9.6 Conclusion. 10 The pharmacoepidemiology of psychiatric medications (Philip S. Wang, Alan M. Brookhart, Christine Ulbricht and Sebastian Schneeweiss). 10.1 Introduction. 10.2 Overview of psychopharmacoepidemiology. 10.3 Sources of data. 10.4 Examples of recent psychopharmacoepidemiologic studies. 10.5 Conclusions. 11 Peering into the future of psychiatric epidemiology (Michaeline Bresnahan, Ezra Susser, Dana March and Bruce Link). 11.1 Introduction. 11.2 Levels of causation: A historical overview. 11.3 Levels of causation. 11.4 Causation over (life) time. 11.5 Examples. 11.6 Framing the future. 12 Studying the natural history of psychopathology (William W. Eaton). 12.1 Introduction. 12.2 Onset. 12.3 Course. 12.4 Outcome. 12.5 Methodological concepts for studying the natural history of psychopathology. 12.6 Conclusion. 13 Symptom scales and diagnostic schedules in adult psychiatry (Jane M. Murphy). 13.1 Introduction. 13.2 North American instruments for epidemiological research. 13.3 North American instruments for psychiatric services and primary care. 13.4 European instruments for psychiatric services and primary care. 13.5 European instruments for epidemiological research. 13.6 Summary. 14 The National Comorbidity Survey (NCS) and its extensions (Ronald C. Kessler). 14.1 Introduction. 14.2 The baseline NCS. 14.3 The NCS follow-up survey (NCS-2). 14.4 The NCS replication survey (NCS-R). 14.5 The NCS-R adolescent supplement (NCS-A). 14.6 The WHO WMH Surveys. 14.7 Overview. 15 Experimental epidemiology (John R. Geddes). 15.1 Introduction. 15.2 Limitations of non-randomised evidence. 15.3 RCTs: The translation of the experimental design into the real world. 15.4 Importance and control of systematic error or bias. 15.5 Importance and control of random error and noise. 15.6 Reporting the results of clinical trials—the CONSORT statement. 15.7 Different clinical questions will prioritise control of different threats to validity and confidence. 15.8 The classification of RCTs. 15.9 Effectiveness trials in schizophrenia. 15.10 Department of Veterans Affairs co-operative study on the cost-effectiveness of Olanzapine (Rosenheck). 15.11 The clinical antipsychotic trials of intervention effectiveness (CATIE) study. 15.12 Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). 15.13 European first-episode schizophrenia trial (EUFEST). 15.14 The size and cost of experimental studies in psychiatry. 15.15 Clinical trials in the future. 16 Epidemiology of Schizophrenia (William W. Eaton, Chuan-Yu Chen and Evelyn J. Bromet). 16.1 Introduction. 16.2 Methods. 16.3 The burden of schizophrenia. 16.4 Natural history. 16.5 Demographic correlates. 16.6 Social risk factors. 16.7 Biological risk factors. 16.8 Prevention. 16.9 Discussion. 17 Epidemiology of depressive disorders (Deborah S. Hasin, Miriam C. Fenton and Myrna M. Weissman). 17.1 Introduction. 17.2 Major depression. 17.3 Dysthymia. 17.4 Summary. 18 Epidemiology of anxiety disorders (Ewald Horwath, Felicia Gould and Myrna M. Weissman). 18.1 Introduction. 18.2 Anxiety disorders. 18.3 Panic disorder. 18.4 Agoraphobia. 18.5 Social phobia. 18.6 Generalised anxiety disorder. 18.7 Obsessive–compulsive disorder. 18.8 Anxiety and affective disorders and mass disasters. 18.9 Future developments. 19 Epidemiology of bipolar disorder in adults and children (Kathleen R. Merikangas and Mauricio Tohen). 19.1 Introduction. 19.2 Epidemiology of bipolar disorder. 19.3 Patterns of comorbidity of bipolar disorder. 19.4 Risk Factors. 19.5 Future directions. 19.6 Summary. 20 Epidemiology of eating disorders (Tracey D. Wade, Anna Keski-Rahkonen and James I. Hudson). 20.1 Introduction. 20.2 Case definition. 20.3 Major prevalence studies. 20.4 Incidence studies. 20.5 Comorbidity. 20.6 Mortality from eating disorders. 20.7 Risk factors. 20.8 Future directions. 21 Epidemiology of alcohol use, abuse and dependence (Deborah A. Dawson, Ralph W. Hingson and Bridget F. Grant). 21.1 Introduction. 21.2 Population estimates of per capita consumption. 21.3 Survey-based estimates of the prevalence of drinking. 21.4 Alcohol-related mortality and morbidity. 21.5 Alcohol and injury. 21.6 Alcohol and chronic disease. 21.7 Diagnostic classification of alcohol use disorders. 21.8 Population estimates, prevalence, incidence and natural course of alcohol use disorders. 21.9 Comorbidity of DSM-IV alcohol use disorders and other psychiatric disorders. 21.10 Summary. 22 Epidemiology of illicit drug use disorders (Wilson M. Compton, Marsha F. Lopez, Kevin P. Conway and Yonette F. Thomas). 22.1 Introduction. 22.2 Drug consumption. 22.3 Definitions. 22.4 Rates of DSM-IV abuse and dependence. 22.5 Global rates of drug use disorders. 22.6 Comorbidities with psychiatric conditions. 22.7 Genetic epidemiology. 22.8 Future opportunities. 22.9 Conclusions. 22.10 Disclaimer. 23 The epidemiology of personality disorders: Findings, methods and concepts (Michael J. Lyons, Beth A. Jerskey and Margo R. Genderson). 23.1 Introduction. 23.2 Substantive findings. 23.3 Course, prognosis and developmental issues. 23.4 Treated prevalence. 23.5 Prevalence of specific personality disorders. 23.6 Antisocial personality disorder. 23.7 Conceptual issues. 23.8 Models of personality disorder. 23.9 Methodological issues. 23.10 Future directions. 24 The epidemiology of depression and anxiety in children and adolescents (Kathleen Ries Merikangas and Erin F. Nakamura). 24.1 Introduction. 24.2 Magnitude of depression and anxiety in children and adolescents. 24.3 Correlates and risk factors. 24.4 Service patterns and impact. 24.5 Summary. 25 Epidemiology of attention deficit hyperactivity disorder (Stephen V. Faraone). 25.1 Introduction. 25.2 Prevalence of ADHD. 25.3 Pharmacoeconomics of ADHD. 25.4 Comorbid psychiatric disorders. 25.5 Demographic risk factors. 25.6 Genetic risk factors. 25.7 Environmental risk factors for ADHD. 25.8 Summary and conclusions. 25.9 Future directions. 26 The epidemiology of autism (Gregory S. Liptak). 26.1 Introduction. 26.2 Background. 26.3 Definition and diagnosis. 26.4 Natural history. 26.5 Prevalence. 26.6 Risk factors. 26.7 Genetic factors. 26.8 Public health impact. 26.9 Associations and causal factors. 26.10 Future directions. 26.11 Summary. 27 Mental illness, women, mothers and their children (Kathryn M. Abel and Vera A. Morgan). 27.1 Introduction. 27.2 The epidemiology of mental illness in women of reproductive age. 27.3 Fertility and fecundity in women with mental illness. 27.4 Maternal mental illness at the time of conception and during pregnancy. 27.5 Gene–environment interactions and offspring outcomes. 27.6 Obstetric complications and risk of adult onset mental disorder in offspring. 27.7 Parental condition. 27.8 Motherhood and perinatal mental illness. 27.9 Designing studies examining the relationship between maternal mental illness and outcomes for their children. 27.10 Conclusions. 28 Epidemiology of suicide and attempted suicide(Dianne Currier and Maria A. Oquendo). 28.1 Introduction. 28.2 Definitions. 28.3 Prevalence of suicide and attempted suicide. 28.4 Risk factors for suicide and attempted suicide. 28.5 Protective factors. 28.6 Conclusions. 29 Epidemiology and geriatric psychiatry (Celia F. Hybels and Dan G. Blazer). 29.1 Introduction. 29.2 Issues of case identification. 29.3 The distribution of cases. 29.4 Aetiological studies. 29.5 Outcome studies. 29.6 Historical trends in the epidemiology of psychiatric disorders in late life. 29.7 Use of health care services. 30 Recent epidemiological studies of psychiatric disorders in Japan (Masayoshi Kawai, Kenji J. Tsuchiya and Nori Takei). 30.1 Introduction. 30.2 Schizophrenia. 30.3 Affective disorders. 30.4 Autism and autism spectrum disorder. 30.5 Summary. 31 Epidemiology of migration and serious mental illness: The example of migrants to Europe (Monica Charalambides, Craig Morgan and Robin M. Murray). 31.1 Introduction. 31.2 Defining the constructs. 31.3 High rates of psychosis in migrants: A genuine finding or methodological artefact? 31.4 Possible explanations. 31.5 Biological considerations. 31.6 Cannabis use. 31.7 Adverse social experiences. 31.8 Mechanisms. 31.9 Implications. 32 Epidemiology of migration substance use disorder in Latin American populations and migration to the United States (Marıa Elena Medina-Mora, Guilherme Borges, Tania Real and Jorge Villatoro). 32.1 Introduction. 32.2 Definitions: What do we understand by migration? 32.3 Countries of origin: Social, political and other reasons that trigger migration. 32.4 Living conditions of migrants in the United States. 32.5 Alcohol and drug use in countries of origin and receiving communities. 32.6 Dependence and treatment rates. 32.7 The process of migrating. 32.8 Migration, substance use and access to services. 32.9 Returning migrants and families left behind. 32.10 Conclusions. 33 Early detection and intervention as approaches for preventing schizophrenia (Ming T. Tsuang, William S. Stone, Margo Genderson and Michael Lyons). 33.1 Introduction. 33.2 Modelling genetic and phenotypic heterogeneity. 33.3 Defining a syndrome of liability using cognitive and clinical characteristics of relatives. 33.4 Gene-based vs. genome-based research. 33.5 Future directions. 33.6 Clinical implications. Acknowledgements. References. Index.

Read more less

Book SynopsisStatistical science plays an increasingly important role in medical research. Over the last few decades, many new statistical methods have been developed which have particular relevance for medical researchers and, with the appropriate software now easily available, these techniques can be used almost routinely to great effect.Table of ContentsPreface. Prologue. 1. The Generalized Linear Model. 1.1 Introduction. 1.2 The generalized linear model – a brief non-technical account. 1.3 Examples of the application of generalized linear models. 1.4 Poisson regression. 1.5 Overdispersion. 1.6 Summary. 2. Generalized Linear Models for Longitudinal Data. 2.1 Introduction. 2.2 Marginal and conditional regression models. 2.3 Marginal and conditional regression models for continuous responses with Gaussian errors. 2.4 Marginal and conditional regression models for non-normal responses. 2.5 Summary. 3. Missing Values, Drop-outs, Compliance and Intention-to-Treat. 3.1 Introduction. 3.2 Missing values and drop-outs. 3.3 Modelling longitudinal data containing ignorable missing values. 3.4 Non-ignorable missing values. 3.5 Compliance and intention-to-treat. 3.6 Summary. 4. Generalized Additive Models. 4.1 Introduction. 4.2 Scatterplot smoothers. 4.3 Additive and generalized additive models. 4.4 Examples of the application of GAMs. 4.5 Summary. 5. Classification and Regression Trees. 5.1 Introduction. 5.2 Tree-based models. 5.3 Birthweight of babies. 5.4 Summary. 6. Survival Analysis I: Cox's Regression. 6.1 Introduction. 6.2 The survivor function. 6.3 The hazard function. 6.4 Cox's proportional hazards model. 6.5 Left truncation. 6.6 Extending Cox's model by stratification. 6.7 Checking the specification of a Cox model. 6.8 Summary. 7. Survival Analysis II: Time-dependent Covariates, Frailty and Tree Models. 7.1 Introduction. 7.2 Time-dependent covariates. 7.3 Random effects models for survival data. 7.4 Tree-structured survival analysis. 7.5 Summary. 8. Bayesian Methods and Meta-analysis. 8.1 Introduction. 8.2 Bayesian methods. 8.3 Meta-analysis. 8.4 Summary. 9. Exact Inference for Categorical Data. 9.1 Introduction. 9.2 Small expected values in contingency table, Yates' correction and Fisher's exact test. 9.3 Examples of the use of exact p-values. 9.4 Logistic regression and conditional logistic regression for sparse data. 9.5 Summary. 10. Finite Mixture Models. 10.1 Introduction. 10.2 Finite mixture distributions. 10.3 Estimating the parameters in finite mixture models. 10.4 Some examples of the application of finite mixture densities in medical research. 10.5 Latent class analysis – mixtures for binary data. 10.6 Summary. Glossary. Appendix A: Statistical Graphics in Medical Invetigations. A.1 Introduction. A.2 Probability plots. A.3 Scatterplots and beyond. A.4 Scatterplot matrices. A.5 Coplots and trellis graphics. Appendix B: Answers to Selected Exercises. References. Index.

Read more less

Book SynopsisBatch Effects and Noise in Microarray Experiments: Sources and Solutions looks at the issue of technical noise and batch effects in microarray studies and illustrates how to alleviate such factors whilst interpreting the relevant biological information. Each chapter focuses on sources of noise and batch effects before starting an experiment, with examples of statistical methods for detecting, measuring, and managing batch effects within and across datasets provided online. Throughout the book the importance of standardization and the value of standard operating procedures in the development of genomics biomarkers is emphasized. Key Features: A thorough introduction to Batch Effects and Noise in Microrarray Experiments. A unique compilation of review and research articles on handling of batch effects and technical and biological noise in microarray data. An extensive overview of current standardization initiatives. All datasets aTable of ContentsList of Contributors xiii Foreword xvii Preface xix 1 Variation, Variability, Batches and Bias in Microarray Experiments: An Introduction 1Andreas Scherer 2 Microarray Platforms and Aspects of Experimental Variation 5John A Coller Jr 2.1 Introduction 5 2.2 Microarray Platforms 6 2.2.1 Affymetrix 6 2.2.2 Agilent 7 2.2.3 Illumina 7 2.2.4 Nimblegen 8 2.2.5 Spotted Microarrays 8 2.3 Experimental Considerations 9 2.3.1 Experimental Design 9 2.3.2 Sample and RNA Extraction 9 2.3.3 Amplification 12 2.3.4 Labeling 13 2.3.5 Hybridization 13 2.3.6 Washing 14 2.3.7 Scanning 15 2.3.8 Image Analysis and Data Extraction 16 2.3.9 Clinical Diagnosis 17 2.3.10 Interpretation of the Data 17 2.4 Conclusions 17 3 Experimental Design 19Peter Grass 3.1 Introduction 19 3.2 Principles of Experimental Design 20 3.2.1 Definitions 20 3.2.2 Technical Variation 21 3.2.3 Biological Variation 21 3.2.4 Systematic Variation 22 3.2.5 Population, Random Sample, Experimental and Observational Units 22 3.2.6 Experimental Factors 22 3.2.7 Statistical Errors 23 3.3 Measures to Increase Precision and Accuracy 24 3.3.1 Randomization 25 3.3.2 Blocking 25 3.3.3 Replication 25 3.3.4 Further Measures to Optimize Study Design 26 3.4 Systematic Errors in Microarray Studies 28 3.4.1 Selection Bias 28 3.4.2 Observational Bias 28 3.4.3 Bias at Specimen/Tissue Collection 29 3.4.4 Bias at mRNA Extraction and Hybridization 30 3.5 Conclusion 30 4 Batches and Blocks, Sample Pools and Subsamples in the Design and Analysis of Gene Expression Studies 33Naomi Altman 4.1 Introduction 33 4.1.1 Batch Effects 35 4.2 A Statistical Linear Mixed Effects Model for Microarray Experiments 35 4.2.1 Using the Linear Model for Design 37 4.2.2 Examples of Design Guided by the Linear Model 37 4.3 Blocks and Batches 39 4.3.1 Complete Block Designs 39 4.3.2 Incomplete Block Designs 39 4.3.3 Multiple Batch Effects 40 4.4 Reducing Batch Effects by Normalization and Statistical Adjustment 41 4.4.1 Between and Within Batch Normalization with Multi-array Methods 43 4.4.2 Statistical Adjustment 46 4.5 Sample Pooling and Sample Splitting 47 4.5.1 Sample Pooling 47 4.5.2 Sample Splitting: Technical Replicates 48 4.6 Pilot Experiments 49 4.7 Conclusions 49 Acknowledgements 50 5 Aspects of Technical Bias 51Martin Schumacher, Frank Staedtler, Wendell D Jones, and Andreas Scherer 5.1 Introduction 51 5.2 Observational Studies 52 5.2.1 Same Protocol, Different Times of Processing 52 5.2.2 Same Protocol, Different Sites (Study 1) 53 5.2.3 Same Protocol, Different Sites (Study 2) 55 5.2.4 Batch Effect Characteristics at the Probe Level 57 5.3 Conclusion 60 6 Bioinformatic Strategies for cDNA-Microarray Data Processing 61Jessica Fahlén, Mattias Landfors, Eva Freyhult, Max Bylesjö, Johan Trygg, Torgeir R Hvidsten, and Patrik Rydén 6.1 Introduction 61 6.1.1 Spike-in Experiments 62 6.1.2 Key Measures – Sensitivity and Bias 63 6.1.3 The IC Curve and MA Plot 63 6.2 Pre-processing 64 6.2.1 Scanning Procedures 65 6.2.2 Background Correction 65 6.2.3 Saturation 67 6.2.4 Normalization 68 6.2.5 Filtering 70 6.3 Downstream Analysis 71 6.3.1 Gene Selection 71 6.3.2 Cluster Analysis 71 6.4 Conclusion 73 7 Batch Effect Estimation of Microarray Platforms with Analysis of Variance 75Nysia I George and James J Chen 7.1 Introduction 75 7.1.1 Microarray Gene Expression Data 76 7.1.2 Analysis of Variance in Gene Expression Data 77 7.2 Variance Component Analysis across Microarray Platforms 78 7.3 Methodology 78 7.3.1 Data Description 78 7.3.2 Normalization 79 7.3.3 Gene-Specific ANOVA Model 81 7.4 Application: The MAQC Project 81 7.5 Discussion and Conclusion 85 Acknowledgements 85 8 Variance due to Smooth Bias in Rat Liver and Kidney Baseline Gene Expression in a Large Multi-laboratory Data Set 87Michael J Boedigheimer, Jeff W Chou, J Christopher Corton, Jennifer Fostel, Raegan O’Lone, P Scott Pine, John Quackenbush, Karol L Thompson, and Russell D Wolfinger 8.1 Introduction 87 8.2 Methodology 89 8.3 Results 89 8.3.1 Assessment of Smooth Bias in Baseline Expression Data Sets 89 8.3.2 Relationship between Smooth Bias and Signal Detection 91 8.3.3 Effect of Smooth Bias Correction on Principal Components Analysis 92 8.3.4 Effect of Smooth Bias Correction on Estimates of Attributable Variability 94 8.3.5 Effect of Smooth Bias Correction on Detection of Genes Differentially Expressed by Fasting 95 8.3.6 Effect of Smooth Bias Correction on the Detection of Strain-Selective Gene Expression 96 8.4 Discussion 97 Acknowledgements 99 9 Microarray Gene Expression: The Effects of Varying Certain Measurement Conditions 101Walter Liggett, Jean Lozach, Anne Bergstrom Lucas, Ron L Peterson, Marc L Salit, Danielle Thierry-Mieg, Jean Thierry-Mieg, and Russell D Wolfinger 9.1 Introduction 101 9.2 Input Mass Effect on the Amount of Normalization Applied 103 9.3 Probe-by-Probe Modeling of the Input Mass Effect 103 9.4 Further Evidence of Batch Effects 108 9.5 Conclusions 110 10 Adjusting Batch Effects in Microarray Experiments with Small Sample Size Using Empirical Bayes Methods 113W Evan Johnson and Cheng li 10.1 Introduction 113 10.1.1 Bayesian and Empirical Bayes Applications in Microarrays 114 10.2 Existing Methods for Adjusting Batch Effect 115 10.2.1 Microarray Data Normalization 115 10.2.2 Batch Effect Adjustment Methods for Large Sample Size 115 10.2.3 Model-Based Location and Scale Adjustments 116 10.3 Empirical Bayes Method for Adjusting Batch Effect 117 10.3.1 Parametric Shrinkage Adjustment 117 10.3.2 Empirical Bayes Batch Effect Parameter Estimates using Nonparametric Empirical Priors 120 10.4 Data Examples, Results and Robustness of the Empirical Bayes Method 121 10.4.1 Microarray Data with Batch Effects 121 10.4.2 Results for Data Set 1 124 10.4.3 Results for Data Set 2 124 10.4.4 Robustness of the Empirical Bayes Method 126 10.4.5 Software Implementation 127 10.5 Discussion 128 11 Identical Reference Samples and Empirical Bayes Method for Cross-Batch Gene Expression Analysis 131Wynn L Walker and Frank R Sharp 11.1 Introduction 131 11.2 Methodology 133 11.2.1 Data Description 133 11.2.2 Empirical Bayes Method for Batch Adjustment 134 11.2.3 Naïve t-test Batch Adjustment 135 11.3 Application: Expression Profiling of Blood from Muscular Dystrophy Patients 135 11.3.1 Removal of Cross-Experimental Batch Effects 135 11.3.2 Removal of Within-Experimental Batch Effects 136 11.3.3 Removal of Batch Effects: Empirical Bayes Method versus t-Test Filter 137 11.4 Discussion and Conclusion 138 11.4.1 Methods for Batch Adjustment Within and Across Experiments 138 11.4.2 Bayesian Approach is Well Suited for Modeling Cross-Experimental Batch Effects 139 11.4.3 Implications of Cross-Experimental Batch Corrections for Clinical Studies 139 12 Principal Variance Components Analysis: Estimating Batch Effects in Microarray Gene Expression Data 141Jianying Li, Pierre R Bushel, Tzu-Ming Chu, and Russell D Wolfinger 12.1 Introduction 141 12.2 Methods 143 12.2.1 Principal Components Analysis 143 12.2.2 Variance Components Analysis and Mixed Models 145 12.2.3 Principal Variance Components Analysis 145 12.3 Experimental Data 146 12.3.1 A Transcription Inhibition Study 146 12.3.2 A Lung Cancer Toxicity Study 147 12.3.3 A Hepato-toxicant Toxicity Study 147 12.4 Application of the PVCA Procedure to the Three Example Data Sets 148 12.4.1 PVCA Provides Detailed Estimates of Batch Effects 148 12.4.2 Visualizing the Sources of Batch Effects 149 12.4.3 Selecting the Principal Components in the Modeling 150 12.5 Discussion 153 13 Batch Profile Estimation, Correction, and Scoring 155Tzu-Ming Chu, Wenjun Bao, Russell S Thomas, and Russell D Wolfinger 13.1 Introduction 155 13.2 Mouse Lung Tumorigenicity Data Set with Batch Effects 157 13.2.1 Batch Profile Estimation 159 13.2.2 Batch Profile Correction 160 13.2.3 Batch Profile Scoring 161 13.2.4 Cross-Validation Results 162 13.3 Discussion 164 Acknowledgements 165 14 Visualization of Cross-Platform Microarray Normalization 167Xuxin Liu, Joel Parker, Cheng Fan, Charles M Perou, and J S Marron 14.1 Introduction 167 14.2 Analysis of the NCI 60 Data 169 14.3 Improved Statistical Power 174 14.4 Gene-by-Gene versus Multivariate Views 178 14.5 Conclusion 181 15 Toward Integration of Biological Noise: Aggregation Effect in Microarray Data Analysis 183Lev Klebanov and Andreas Scherer 15.1 Introduction 183 15.2 Aggregated Expression Intensities 185 15.3 Covariance between Log-Expressions 186 15.4 Conclusion 189 Acknowledgements 190 16 Potential Sources of Spurious Associations and Batch Effects in Genome-Wide Association Studies 191Huixiao Hong, Leming Shi, James C Fuscoe, Federico Goodsaid, Donna Mendrick, and Weida Tong 16.1 Introduction 191 16.2 Potential Sources of Spurious Associations 192 16.2.1 Spurious Associations Related to Study Design 194 16.2.2 Spurious Associations Caused in Genotyping Experiments 195 16.2.3 Spurious Associations Caused by Genotype Calling Errors 195 16.3 Batch Effects 196 16.3.1 Batch Effect in Genotyping Experiment 196 16.3.2 Batch Effect in Genotype Calling 197 16.4 Conclusion 201 Disclaimer 201 17 Standard Operating Procedures in Clinical Gene Expression Biomarker Panel Development 203Khurram Shahzad, Anshu Sinha, Farhana Latif, and Mario C Deng 17.1 Introduction 203 17.2 Theoretical Framework 204 17.3 Systems-Biological Concepts in Medicine 204 17.4 General Conceptual Challenges 205 17.5 Strategies for Gene Expression Biomarker Development 205 17.5.1 Phase 1: Clinical Phenotype Consensus Definition 206 17.5.2 Phase 2: Gene Discovery 207 17.5.3 Phase 3: Internal Differential Gene List Confirmation 209 17.5.4 Phase 4: Diagnostic Classifier Development 209 17.5.5 Phase 5: External Clinical Validation 210 17.5.6 Phase 6: Clinical Implementation 211 17.5.7 Phase 7: Post-Clinical Implementation Studies 212 17.6 Conclusions 213 18 Data, Analysis, and Standardization 215Gabriella Rustici, Andreas Scherer, and John Quackenbush 18.1 Introduction 215 18.2 Reporting Standards 216 18.3 Computational Standards: From Microarray to Omic Sciences 219 18.3.1 The Microarray Gene Expression Data Society 219 18.3.2 The Proteomics Standards Initiative 220 18.3.3 The Metabolomics Standards Initiative 220 18.3.4 The Genomic Standards Consortium 220 18.3.5 Systems Biology Initiatives 221 18.3.6 Data Standards in Biopharmaceutical and Clinical Research 221 18.3.7 Standards Integration Initiatives 222 18.3.8 The MIBBI project 223 18.3.9 OBO Foundry 223 18.3.10 FuGE and ISA-TAB 223 18.4 Experimental Standards: Developing Quality Metrics and a Consensus on Data Analysis Methods 226 18.5 Conclusions and Future Perspective 228 References 231 Index 245

Read more less

Book SynopsisPraise for the Second Edition: ...a grand feast for biostatisticians. It stands ready to satisfy the appetite of any pharmaceutical scientist with a respectable statistical appetite. Journal of Clinical Research Best Practices The Third Edition of Design and Analysis of Clinical Trials provides complete, comprehensive, and expanded coverage of recent health treatments and interventions. Featuring a unified presentation, the book provides a well-balanced summary of current regulatory requirements and recently developed statistical methods as well as an overview of the various designs and analyses that are utilized at different stages of clinical research and development. Additional features of this Third Edition include: New chapters on biomarker development and target clinical trials, adaptive design, trials for evaluating diagnostic devices, statistical methods for translational medicine, and traditional Chinese medicine Trade Review�In summary, this third edition is an impressive expansion beyond a remarkable second edition. This book would be good reference for biostatisticians, clinical researchers, and pharmaceutical scientists in clinical research and development.� (Journal of Biopharmaceutical Statistics, 1 July 2014)"Design and Analysis of Clinical Trials: Concepts and Methodologies, Third Edition is a grand feast for biostatisticians. It stands ready to satisfy the appetite of any pharmaceutical scientist with a respectable statistical appetite...Essential reading for clinical research professionals." (Journal of Clinical Research Best Practice February 2014)Table of ContentsPreface xi PART I PRELIMINARIES 1 Introduction 3 1.1 What are Clinical Trials?, 3 1.2 History of Clinical Trials, 4 1.3 Regulatory Process and Requirements, 10 1.4 Investigational New Drug Application, 17 1.5 New Drug Application, 24 1.6 Clinical Development and Practice, 31 1.7 AIMS and Structure of the Book, 42 2 Basic Statistical Concepts 45 2.1 Introduction, 45 2.2 Uncertainty and Probability, 46 2.3 Bias and Variability, 49 2.4 Confounding and Interaction, 57 2.5 Descriptive and Inferential Statistics, 66 2.6 Hypotheses Testing and p-Values, 68 2.7 Clinical Significance and Clinical Equivalence, 75 2.8 Reproducibility and Generalizability, 79 3 Basic Design Considerations 85 3.1 Introduction, 85 3.2 Goals of Clinical Trials, 86 3.3 Target Population and Patient Selection, 90 3.4 Selection of Controls, 97 3.5 Statistical Considerations, 105 3.6 Other Issues, 112 3.7 Discussion, 115 4 Randomization and Blinding 117 4.1 Introduction, 117 4.2 Randomization Models, 118 4.3 Randomization Methods, 124 4.4 Implementation of Randomization, 144 4.5 Generalization of Controlled Randomized Trials, 149 4.6 Blinding, 153 4.7 Discussion, 160 PART II DESIGNS AND THEIR CLASSIFICATIONS 5 Designs for Clinical Trials 165 5.1 Introduction, 165 5.2 Parallel Group Designs, 167 5.3 Clustered Randomized Designs, 172 5.4 Crossover Designs, 177 5.5 Titration Designs, 185 5.6 Enrichment Designs, 191 5.7 Group Sequential Designs, 195 5.8 Placebo-Challenging Designs, 197 5.9 Blinded Reader Designs, 203 5.10 Discussion, 207 6 Designs for Cancer Clinical Trials 211 6.1 Introduction, 211 6.2 General Considerations for Phase I Cancer Clinical Trials, 213 6.3 Single-Stage Up-and-Down Phase I Designs, 214 6.4 Two-Stage Up-and-Down Phase I Designs, 217 6.5 Continual Reassessment Method Phase I Designs, 219 6.6 Optimal and Flexible Multiple-Stage Designs, 222 6.7 Randomized Phase II Designs, 229 6.8 Discussion, 232 7 Classification of Clinical Trials 237 7.1 Introduction, 237 7.2 Multicenter Trials, 238 7.3 Superiority Trials, 245 7.4 Active Control and Equivalence/Noninferiority Trials, 248 7.5 Dose–Response Trials, 261 7.6 Combination Trials, 266 7.7 Bridging Studies and Global Trials, 278 7.8 Vaccine Clinical Trials, 285 7.9 QT Studies, 291 7.10 Discussion, 299 PART III ANALYSIS OF CLINICAL DATA 8 Analysis of Continuous Data 305 8.1 Introduction, 305 8.2 Estimation, 306 8.3 Test Statistics, 310 8.4 Analysis of Variance, 316 8.5 Analysis of Covariance, 323 8.6 Nonparametric Methods, 325 8.7 Repeated Measures, 332 8.8 Discussion, 341 9 Analysis of Categorical Data 343 9.1 Introduction, 343 9.2 Statistical Inference for One Sample, 345 9.3 Inference of Independent Samples, 358 9.4 Ordered Categorical Data, 364 9.5 Combining Categorical Data, 368 9.6 Model-Based Methods, 374 9.7 Repeated Categorical Data, 382 9.8 Discussion, 387 10 Censored Data and Interim Analysis 389 10.1 Introduction, 389 10.2 Estimation of the Survival Function, 391 10.3 Comparison Between Survival Functions, 399 10.4 Cox’s Proportional Hazard Model, 405 10.5 Calendar Time and Information Time, 419 10.6 Group Sequential Methods, 424 10.7 Discussion, 438 11 Sample Size Determination 441 11.1 Introduction, 441 11.2 Basic Concept, 442 11.3 Two Samples, 447 11.4 Multiple Samples, 456 11.5 Censored Data, 459 11.6 Dose–Response Studies, 464 11.7 Crossover Designs, 471 11.8 Equivalence and Noninferiority Trials, 481 11.9 Multiple-Stage Design in Cancer Trials, 490 11.10 Multinational Trials, 490 11.11 Comparing Variabilities, 500 11.12 Discussion, 517 PART IV ISSUES IN EVALUATION 12 Issues in Efficacy Evaluation 521 12.1 Introduction, 521 12.2 Baseline Comparison, 523 12.3 Intention-to-Treat Principle and Efficacy Analysis, 528 12.4 Adjustment for Covariates, 536 12.5 Multicenter Trials, 541 12.6 Multiplicity, 548 12.7 Data Monitoring, 558 12.8 Use of Genetic Information for Evaluation of Efficacy, 564 12.9 Sample Size Reestimation, 570 12.10 Discussion, 572 13 Safety Assessment 573 13.1 Introduction, 573 13.2 Extent of Exposure, 574 13.3 Coding of Adverse Events, 582 13.4 Analysis of Adverse Events, 595 13.5 Analysis of Laboratory Data, 602 13.6 Analysis of QT/QTc Prolongation, 610 13.7 Discussion, 615 PART V RECENT DEVELOPMENT 14 Biomarkers and Targeted Clinical Trials 619 14.1 Introduction, 619 14.2 Concepts and Strategies, 620 14.3 Biomarker Development and Validation, 623 14.4 Designs of Targeted Clinical Trials, 630 14.5 Analyses of Targeted Clinical Trials, 640 14.6 Discussion, 647 15 Trials for Evaluating Accuracy of Diagnostic Devices 649 15.1 Introduction, 649 15.2 Study Design, 651 15.3 Measures of Diagnostic Accuracy, 656 15.4 Reporting Results, 663 15.5 Sample Size Estimation, 672 15.6 Discussion, 675 16 Statistical Methods in Translational Medicine 677 16.1 Introduction, 677 16.2 Biomarker Development, 678 16.3 Bench-to-Bedside, 682 16.4 Animal Model Versus Human Model, 689 16.5 Translation in Study Endpoints, 691 16.6 Bridging Studies, 696 16.7 Discussion, 699 16.8 Appendix, 700 17 Adaptive Clinical Trial Designs 703 17.1 Introduction, 703 17.2 What Is Adaptive Design?, 704 17.3 Well-Understood and Less Well-Understood Designs, 709 17.4 Clinical/Statistical and Regulatory Perspectives, 713 17.5 Impact of Protocol Amendments, 716 17.6 Challenges in By-Design Adaptations, 721 17.7 Obstacles of Retrospective Adaptations, 727 17.8 Discussion, 729 18 Traditional Chinese Medicine 733 18.1 Introduction, 733 18.2 Fundamental Differences, 734 18.3 Basic Considerations of TCM Clinical Trials, 741 18.4 Other Issues in TCM Research and Development, 744 18.5 Consortium for Globalization of Traditional Chinese Medicine, 751 18.6 Discussion, 752 PART VI CONDUCT OF CLINICAL TRIALS 19 Preparation and Implementation of a Clinical Protocol 755 19.1 Introduction, 755 19.2 Structure and Components of a Protocol, 756 19.3 Points to be Considered and Common Pitfalls During Development and Preparation of a Protocol, 762 19.4 Common Departures for Implementation of a Protocol, 765 19.5 Monitoring, Audit, and Inspection, 771 19.6 Quality Assessment of a Clinical Trial, 775 19.7 Discussion, 777 20 Data Management of a Clinical Trial 779 20.1 Introduction, 779 20.2 Regulatory Requirements, 781 20.3 Development of Case Report Forms, 783 20.4 Database Development, 787 20.5 Data Entry, Query, and Correction, 788 20.6 Data Validation and Quality, 791 20.7 Database Lock, Archive, and Transfer, 792 20.8 Critical Issues, 795 References 799 Appendix A 845 Index 851

Read more less

Book Synopsis A simple and systematic guide to the planning and performance of investigations concerned with health and disease and with health care Offers researchers help in choosing a topic and to think about shaping objectives and ideas and to link these with the appropriate choice of method Fully updated with new sections on the use of the Web and computer programmes freely available in the planning, performance or analysis of studies Table of ContentsPreface vii 1. First steps 1 2. Types of investigation 13 3. Stages of an investigation 35 4. Formulating the objectives 39 5. The objectives of evaluative studies 49 6. The study population 61 7. Control groups 69 8. Sampling 77 9. Selecting cases and controls for case-control studies 91 10. The variables 101 11. Defining the variables 109 12. Definitions of diseases 117 13. Scales of measurement 125 14. Composite scales 133 15. Methods of collecting data 143 16. Reliability 151 17. Validity 161 18. Interviews and self-administered questionnaires 179 19. Constructing a questionnaire 193 20. Surveying the opinions of a panel: consensus methods 203 21. The use of documentary sources 209 22. Planning the records 225 23. Planning the handling of data 233 24. Pretests and other preparations 241 25. Collecting the data 247 26. Statistical analysis 251 27. Interpreting the findings 259 28. Making sense of associations 269 29. Application of the study findings 297 30. Writing a report 305 31. Rapid epidemiological methods 313 32. Clinical trials 325 33. Programme trials 345 34. Community-oriented primary care 357 35. Using the Web for health research 373 Appendix A Community appraisal: a checklist 383 Appendix B Random numbers 387 Appendix C Free computer programs 389 Index 407

Read more less

Book SynopsisA respected introduction to biostatistics, thoroughly updated and revised The first edition of Biostatistics: A Methodology for the Health Sciences has served professionals and students alike as a leading resource for learning how to apply statistical methods to the biomedical sciences. This substantially revised Second Edition brings the book into the twenty-first century for today's aspiring and practicing medical scientist. This versatile reference provides a wide-ranging look at basic and advanced biostatistical concepts and methods in a format calibrated to individual interests and levels of proficiency. Written with an eye toward the use of computer applications, the book examines the design of medical studies, descriptive statistics, and introductory ideas of probability theory and statistical inference; explores more advanced statistical methods; and illustrates important current uses of biostatistics. New to this edition are discussions of LongitTrade Review"…an excellent introductory biostatics book with several examples and easy to understand interpretations of data analysis results." (Journal of Statistical Computation and Simulation, September 2005) "The book would serve as a good springboard for structuring an introductory biostatistics course…" (The American Statistician, August 2005) "...the book will be a great resource for new readers as well as professionals in the field of health research." (E-STREAMS, May 2005) "...this comprehensive book should continue to merit consideration by anyone looking for a desktop reference in biostatistics." (Technometrics, May 2005) “…this second edition adds two new chapters: one on randomised clinical trials, and another on longitudinal data analysis.” (Journal of Applied Statistics, Vol.32, No.3, April 2005) "Beyond comprehensiveness, the differentiating characteristics of this textbook is the use of medical examples...a text that can be fully appreciated by those seeking a technical statistical reference…" (The Annals of Pharmacotherapy, March 2005) “…enjoyable reading…approachable and comprehensible…a useful addition to the bookshelf of any biomedical researcher…” (Journal of the Royal Statistical Society, Series A, Vol.168, No.2, March 2005) “…this updated edition will ensure the ongoing usefulness of this valuable resource…” (Short Book Reviews, Vol.24, No.3, December 2004) "…chock full of information and careful examination…scientists and researchers who access this information will gain much new insight…" (Electric Review, October/ November 2004) "The authors have dealt with the subject matter in truly comprehensive terms… scientists and researchers who access this information will gain much new insight..." (Electric Review, July/August 2004) Table of ContentsPreface to the First Edition. Preface to the Second Edition. 1. Introduction to Biostatistics. 2. Biostatistical Design of Medical Studies. 3. Descriptive Statistics. 4. Statistical Inference: Populations and Samples. 5. One- and Two-Sample Inference. 6. Counting Data. 7. Categorical Data: Contingency Tables. 8. Nonparametric, Distribution-Free and Permutation Models: Robust Procedures. 9. Association and Prediction: Linear Models with One Predictor Variable. 10. Analysis of Variance. 11. Association and Prediction: Multiple Regression Analysis, Linear Models with Multiple Predictor Variables. 12. Multiple Comparisons. 13. Discrimination and Classification. 14. Principal Component Analysis and Factor Analysis. 15. Rates and Proportions. 16. Analysis of the Time to an Event: Survival Analysis. 17. Sample Sizes for Observational Studies. 18. Longitudinal Data Analysis. 19. Randomized Clinical Trials. 20. A Personal Postscript. Appendix. Author Index. Subject Index. Symbol Index.

Read more less

Book SynopsisIntroduces applied research areas and a number of real-life questions and examples with basic methods in nonparametric statistics, including the concept of censoring, which distinguishes survival analysis from other areas of statistics.Table of ContentsBasic Concepts in Survival Analysis. Estimation of Functions and Parameters. Comparison of Survival Distributions. Correlation and Regression Analyses. Appendices. References. Index.

Read more less